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Abstract 
Prostate cancer is a biologically heterogenous disease with considerable variation in 
clinical aggressiveness. Gleason grade, the universally accepted method for 
classification of prostate cancer, is subjective and gives limited predictive information 
regarding prostate cancer progression. There is a clinical need for an objective, reliable 
tool to help pathologists improve current prostate tissue analysis methods and better 
assess the malignant potential of prostate tumours. Fourier Transform Infrared (FTIR) 
microspectroscopy is a powerful bioanalytical technique that uses infrared light to 
interrogate biological tissue. The studies detailed in this thesis examine the ability of 
FTIR combined with multivariate analysis to discriminate between benign, 
premalignant and malignant prostate pathology in snap frozen, paraffinated and 
deparaffinated tissue.   
Prostate tissue was collected during and after urological procedures performed between 
2005 and 2008. The tissue was analysed utilising a bench top FTIR system in point and 
image mapping modes. The histology under interrogation was identified by a uro-
pathologist. Multivariate analysis was applied to the spectral dataset obtained. FTIR 
performance was evaluated. 
FTIR was able to reproducibly discriminate between benign and malignant prostate 
tissue in a pilot study. Cross validated diagnostic algorithms, constructed from the 
spectral dataset in this experiment, achieved sensitivities and specificities of 95% and 
89% respectively. 
FTIR analysis of transverse paraffinated and deparaffinated radical prostatectomy 
sections achieved good differentiation of the benign, premalignant and malignant 
 
pathology groups. However the performance of diagnostic algorithms constructed from 
this dataset under cross validation was poor. 
The work in this thesis illustrates the potential of FTIR to provide an objective method 
to assist the pathologist in the assessment of prostate samples. The limitations of the 
technique and directions for future work are presented. 
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 1
“ I had prostate cancer. It was rather painful and, in many ways, life changing ” 
Sir Roger Moore 1927- 
1  Introduction 
Prostate cancer is the most common cancer in men in the United Kingdom and the 
second most common male cancer in the world1. Despite a dramatic rise in prostate 
cancer incidence over the last decade, its aetiology and natural history remain poorly 
understood. Currently, histopathological analysis of prostate tissue obtained at 
transrectal ultrasound (TRUS) guided biopsy is the gold standard for diagnosis of 
prostate cancer and contributes to treatment strategy. Pathological interpretation of 
prostate specimens is time consuming and subjective. Although its current place as a 
standard is undisputed, it has an inherent weakness: - inter observer variation, which has 
been demonstrated repeatedly2,3,4,5. There is a need for alternative innovations to 
improve the cost, speed and accuracy of prostate cancer diagnosis. Progress in this field 
would improve patient management in addition to gaining a better understanding of the 
disease. 
Fourier Transform Infrared Spectroscopy (FTIR) is an optical technology capable of 
interrogating materials and objectively determining biochemical composition. FTIR is 
in widespread use in industry however its’ potential biomedical applications have only 
recently been evaluated. The studies which are detailed in this thesis investigate the 
ability of FTIR to discriminate between common prostate pathologies and identify 
where FTIR may create a niche in clinical practice. 
This chapter describes the normal anatomy and function of the prostate in addition to 
common pathological variants. The pathway to a prostate cancer diagnosis is outlined in 
addition to current management controversies. To conclude the literature regarding the 
biomedical applications of FTIR is reviewed and the aims and objectives of this thesis 
are stated. 
1.1 The Prostate Gland 
1.1.1  The Anatomy of the Normal Prostate  
The prostate gland was first described anatomically in 1538 by Vesalius and was named 
“the prostate” in 1611 by Casper Bartholin6. The prostate is an exocrine gland which 
forms part of the male reproductive system. The gland secretes an alkaline fluid that 
makes up a significant component of seminal fluid. The gland is inversely conical in 
shape and situated in the true pelvis (see Figure 1.1). The base of the prostate is in 
continuity with the bladder neck, the gland surrounds the first part of the urethra and the 
apex opposes the urogenital diaphragm. The anterior and posterior relations of the gland 
are the symphysis pubis and the rectum respectively7. The seminal vesicles which also 
contribute fluid towards the ejaculate are attached to the base of the prostate. The 
vesicles are separated from the rectum by the rectovesical pouch.  The glands of the 
seminal vesicles merge and join the ductus deferens to form the ejaculatory duct7. 
 
Figure 1.1 Median sagittal section of the male pelvis8 
The arterial supply to the prostate is derived from the internal iliac artery entering 
through neurovascular pedicles on the superolateral aspect of the gland bilaterally. 
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Venous drainage is into the prostatic plexus, in the pericapsular region, and 
subsequently into the internal iliac veins9. 
The lymphatic drainage of the prostate is primarily into the internal iliac nodes. The 
external and sacral nodes also receive drainage. These nodes are usually the first site of 
extraprostatic lymphatic spread from prostate cancer.  
The prostate is supplied by a rich neural plexus. The acini receive parasympathetic 
(cholinergic) innervation from the pelvic splanchnic nerves. The stroma which contract 
to empty the gland during ejaculation receive sympathetic innervation (adrenergic) from 
the inferior hypogastric plexus. The nerves penetrate the gland and may provide a route 
for intra or extraprostatic cancer spread. One theory is that this spread occurs because 
the nerves offer the path of least resistance. When seen as a pathological entity it is 
termed perineural invasion10. 
 
   
 
 
 
 
 
Figure 1.2 Sagittal and transverse prostate views illustrating McNeal’s zonal 
anatomy11 
The currently accepted anatomy of the prostate gland was first described by McNeal in 
1968. In his model, illustrated in figure 1.2, the prostate is divided into three main 
glandular zones (central, transitional, peripheral) orientated around the prostatic urethra. 
The key reference point is the 35o angle at the midpoint of the prostatic urethra which 
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separates the prostate into proximal and distal segments. The bulge of the 
verumontanum located on the posterior wall of the distal segment, defines the point of 
separation. The ejaculatory ducts and greater than 90% of the glands of the prostate 
empty into the distal urethra12,13,14 .  
Each zone has a different glandular organisation and proclivity for disease:- 
The central zone (CZ) encircles the ejaculatory ducts and is cone shaped, extending 
from the prostate base to the verumontanum. The CZ accounts for approximately 25% 
of normal prostatic volume. Approximately 10% of prostate cancers arise in the CZ14. 
The transitional zone (TZ) forms two pear shaped lobes on either side of the proximal 
urethra and accounts for 5% of normal prostate volume. The glands in the transitional 
zone are the primary site of benign prostatic hyperplasia (BPH). Approximately 15-20% 
of prostate cancers arise in the TZ14. 
The peripheral zone (PZ) surrounds the central and transitional zones in the basal 
portion of the gland and the distal prostatic urethra. The PZ constitutes the majority of 
normal prostate volume (70%). 70-75% of carcinomas arise in the PZ and it is a 
common site of prostatic intraepithelial neoplasia (PIN), inflammation, atrophy and 
occasionally hyperplasia14. 
The periurethral zone is composed of small glands around the proximal urethra lying 
within the confines of the preprostatic sphincter14. 
Important non glandular elements complete the model. Fibromuscular stroma, 
composed of compact collagen and smooth muscle bundles, surrounds the prostate and 
is sometimes described as a ‘capsule’. This is not a true capsule but is clinically 
important in defining and evaluating extraprostatic extension of carcinoma. The 
preprostatic sphincter forms a sleeve of smooth muscle fibres around the proximal 
urethra. The sphincter prevents retrograde flow of seminal fluid when it contracts during 
ejaculation. Striated muscle fibres are present inferior to the prostate apex. These are 
continuous with the external urethral sphincter and are responsible for urinary 
continence14. 
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1.1.2 Relevance of Prostate Anatomy in Current Clinical Practice  
The investigation and management of disorders of the prostate requires sound 
knowledge and application of anatomy. For example, the verumontanum is a key 
landmark for endoscopic procedures of the lower urinary tract. When performing 
endoscopic surgery to relieve bladder outflow obstruction (transurethral resection of the 
prostate (TURP) or bladder neck incision (BNI)), resection is not pursued distal to the 
verumontanum to avoid damage to the external urethral sphincter and preserve 
continence after surgery (Illustrated in figure 1.3). Pelvic lymph nodes (usually the 
obturator nodes) may be sampled during radical prostatectomy (surgery to remove the 
prostate in patients with prostate cancer) this may provide useful tumour staging 
information. The obturator nodes are usually the first to be involved in metastatic 
spread. 
 
V = Verumontanum 
L = Lateral lobe prostate 
L L
V
Figure 1.3 The internal anatomy of the prostate viewed at TURP 
The regions of the prostate sampled by core biopsy and transurethral resection of the 
prostate are likely to be quite different. Transrectal ultrasound guided core biopsies will 
mostly consist of tissue from the peripheral zone, seldom the central or transitional 
zones. TURP specimens are more likely to consist of tissue from the urethra, bladder 
neck, periurethral zone, transitional zone and anterior fibromuscular stroma14. Well 
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differentiated carcinoma found incidentally in TURP specimens is more likely to 
represent carcinoma which has arisen in the transitional zone. Poorly differentiated 
carcinoma in TURP specimens may represent tumour originating in the peripheral zone 
that invades the transitional zone15. In this thesis FTIR has been used to interrogate core 
biopsy tissue, TURP specimens and prostate sections in their entirety to establish 
spectroscopic parameters for all prostate tissue.  
1.1.3 The Histology of the Normal Prostate 
The prostate gland has a tubulo-alveolar organisation; the main zones (CZ, TZ, and PZ) 
all contain ducts and glands. The typical gland is lined by a basement membrane (BM), 
which is composed of type IV collagen, fibronectin, laminin, heparin sulphate and 
entactin16. The BM is separated from the secretory epithelial cells by a layer of basal 
cells lying parallel to the BM. These basal cells have little discernable cytoplasm and 
darkly stained nuclei12. Although basal cell function is poorly understood, histologically 
basal cells are important as their presence differentiates between benign disease and 
adenocarcinoma when they are not present. The epithelium consists of columnar shaped 
cells that secrete proteins such as prostate specific antigen (PSA) and prostatic acid 
phosphatase (PAP) into the seminal plasma17. The glands secrete mucins and produce 
lipofuscin18.  Biochemical products including citric acid and acid phosphatase are also 
secreted19. The glands empty into prostatic ducts and in turn the prostatic urethra. Ducts 
are lined by transitional cell epithelium just before they enter the urethra. 
1.1.4 Variation in Zonal Histology and Biochemistry 
Variation in normal histology exists between zones. The glands of the peripheral and 
transitional zones have rounded contours. Central zone glands are larger, more complex 
and often located in lobules around central ducts, ridges and arches. Central zone 
architecture may be mistaken for hyperplasia or prostatic intraepithelial neoplasia. 
Peripheral zone stroma is loosely woven with randomly arranged smooth muscle. 
Transitional zone stroma contains more compact, interlacing smooth muscle bundles. 
The stroma in the central zone is less abundant but contains compact smooth muscle 
fibres. 
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Biochemically, the central zone is the only zone which produces pepsinogen II and 
tissue plasminogen activator20,21. Lectin binding patterns have been found to reflect 
selective binding to specific cellular glycoconjugates which differ between the central 
and peripheral zone22.  
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1.2 Pathology of the Prostate 
The focus of pathological analysis of prostate tissue in routine clinical practice is 
primarily to identify whether and to what extent prostate cancer is present. The lay term 
cancer is frequently used to equate with malignant neoplasm. The term neoplasm (also 
known as tumour) is defined as an abnormal, poorly controlled proliferation of cells. A 
benign neoplasm remains localised in its tissue of origin with no propensity to spread. A 
malignant tumour comprises cells with the ability to invade adjacent tissues and spread 
to distant sites in the body, a process known as metastasis. Knowledge of benign 
pathologies of the prostate in addition to possible premalignant lesions is essential to 
enable differentiation between benign and malignant pathologies. This section will 
concentrate on common pathologies of the prostate that will be interrogated by FTIR in 
this thesis. 
1.2.1 Benign Prostatic Hyperplasia 
Benign prostatic hyperplasia (BPH) is common. The term is often used in relation to the 
symptom complex that is associated with it. Clinically, BPH is characterised by voiding 
and storage symptoms of variable severity23. Progression of the disease may lead to 
recurrent urinary tract infections, bladder calculi or urinary retention. BPH is however a 
pathological diagnosis and therefore can only accurately be made after prostate tissue 
analysis. 
Histologically, BPH represents specific deviations in architecture rather than simply an 
increase in cell population. Macroscopically the identification of hyperplastic glandular 
acini separated by fibrous stroma in a nodular pattern confirms the pathological 
diagnosis. In the transitional zone medium and large BPH glands may display 
architectural complexity and papillary infolding. Some nodules are cystically dilated 
and may contain a milky fluid. Other nodules contain calcified concretion ‘corpora 
amylacea’ – well circumscribed round structures with concentric lamellar rings.  
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Periurethral nodules have an abundance of pale ground material and a few collagen 
fibres. Microscopically the acini are tightly packed, lined by tall columnar epithelial 
cells with small basal nuclei24, as seen in Figure 1.4. 
 
Figure 1.4 Photomicrograph of Benign Prostatic Hyperplasia25 
The epithelium usually has a distinct double layer of secretory and basal cells. BPH 
cells are often thrown into folds however the nuclei remain aligned in a single row, 
which differs from PIN where the nuclei are irregularly arranged.  The cytoplasm in 
BPH is abundant and clear.  
BPH is intimately related to ageing26, its presence in autopsy studies rises from 
approximately 20% in men aged 41-50, to 50% in men aged 51-60 and to over 90% in 
men older than 8027. Although BPH is not life threatening, the effect of the lower 
urinary tract symptoms resulting from bladder outflow obstruction on patient quality of 
life can be significant28. Lifestyle modifications and medication29 form the mainstay of 
conservative treatments for BPH. Surgical treatments range from insertion of prostatic 
stents which maintain prostatic urethral patency to enucleation of prostate tissue by 
either open or endoscopic techniques. TURP is a commonly performed endoscopic 
operation to relive bladder outflow obstruction in men30, and is one of the sources of 
prostate tissue obtained in this project. 
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1.2.2 Prostatitis 
Inflammation of the prostate is termed prostatitis. The condition usually follows 
infection of the bladder or urethra, is benign, may be acute or chronic and have either 
definitive (for example: surgical instrumentation) or idiopathic precipitants. Acute 
bacterial prostatitis is the most common urologic diagnosis in men younger than 50 
years old31. Common causative organisms include E. Coli, Proteus and Chlamydia. 
Clinically patients may report a number of symptoms: fever, urinary frequency and 
urgency, dysuria, haematospermia and pain in the lower back, rectum and perineum. 
Acute bacterial prostatitis may culminate in abscess formation and the condition 
requires prompt medical treatment. The diagnosis of acute prostatitis is made from 
assessment of the clinical presentation, positive urine or blood cultures and the 
examination finding of a tender prostate at digital rectal examination. Chronic prostatitis 
may be asymptomatic or present with chronic pelvic pain. Men with chronic prostatitis 
may present solely with an elevated PSA and an abnormal digital rectal examination. In 
these men prostatitis may be diagnosed histologically from a prostate biopsy whilst 
being investigated for a suspected prostate cancer. 
The peripheral zone of the prostate is reported to be the most susceptible to prostatitis. 
The transitional zone is less predisposed but may display features of secondary 
inflammation in the presence of prostatic hyperplasia. The central zone is considered 
resistant to inflammation. Microscopically in acute prostatitis sheets of neutrophils are 
visualised in and around prostatic ducts and acini, in addition to desquamated 
epithelium and debris (see Figure 1.5). The stroma is oedematous, haemorrhagic and 
microabscesses may be observed. Granulomas, lymphocytes, plasma cells and 
macrophages may also be found in the prostate stroma in the presence of chronic 
disease32. 
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 Figure 1.5 Photomicrograph of acute bacterial prostatitis 
1.2.3 Atrophy of the Prostate 
Atrophy is a benign process generally associated with ageing but may occur as an end 
result of inflammation. It is characterised by shrinkage of distal ductules, glands and 
stroma. Atrophy affects predominantly the peripheral zone. Clinically atrophy may be 
seen as a hyperechoic lesion on transrectal ultrasound which may be suspicious for 
carcinoma. It is important to be aware of atrophy as an entity because a lobular 
glandular organisation may not be apparent causing it to be mistaken for carcinoma of 
the prostate32. 
 1.2.4 Prostatic Intraepithelial Neoplasia 
Prostatic intraepithelial neoplasia (PIN) may be a precursor of invasive cancer33,34,35 . 
The term was first adopted by Bostwick and Brawer to describe all forms of atypical 
and malignant lesions of epithelial cells confined to the lumens of ducts and acini36. PIN 
is characterised by an intraluminal proliferation of secretory epithelium that 
demonstrates a spectrum of cytological changes. High grade PIN may strongly resemble 
carcinoma. Although initially described in three grades, the majority of pathologists 
now only report high grade PIN due to difficulties in consistency distinguishing the 
features of early PIN and the clinical significance of high grade PIN due to its strong 
association with invasive carcinoma37. PIN has been demonstrated to be more prevalent 
 11
with age38,39, and its presence is more common in prostatectomy specimens with 
carcinoma present36,39,40 . In core biopsies the incidence of isolated high grade PIN 
(without cancer) has been reported to be between 0.7 and 16.5% (mean 4%)41. PIN may 
predate the diagnosis of cancer by five years38,39. The identification of isolated high 
grade PIN within a specimen clinically may result in a higher index of suspicion for the 
presence of malignancy.  
 
Figure 1.6 Photomicrograph of High Grade Prostatic Intraepithelial Neoplasia42 
 
Microscopic features of high grade PIN are large prominent nucleoli, hyperchromasia 
and cytoplasmic eosinophilia, as seen in Figure 1.6. PIN glands stand out from normal 
ones because of their basophilic appearance. There may be partial loss of the basal cell 
layer. Four major architectural patterns have been described: tufted, micropapillary, 
cribriform and flat. PIN shares many similarities with prostate adenocarcinoma: it is 
predominantly identified in the peripheral zone, often adjacent to carcinoma43,44,45 and it 
demonstrates similar patterns of spread. The first pattern is the replacement of normal 
luminal secretory epithelium by neoplastic cells. The second is pagetoid spread along 
ducts, characterised by invagination of neoplastic cells between the basal layer and the 
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columnar secretory cell layer. The third pattern is direct microinvasion through the 
ductal or acinar wall, disrupting the basal cell layer and basement membrane36,46,47 .  
1.2.5 Atypical Small Acinar Proliferation 
Atypical small acinar proliferation (ASAP) describes a small focus of prostate glands 
that is suspicious but not diagnostic of Adenocarcinoma. ASAP is present in 2% of 
prostate core biopsies48. Microscopically ASAP has small acini lined with cytologically 
abnormal epithelial cells. The columnar cells have prominent nuclei containing nucleoli; 
the basal layer may be absent but the basement membrane is intact. Difficulties in 
diagnosing ASAP are acknowledged as it may only be present in small foci. Isolated 
ASAP in a biopsy raises the suspicion that cancer focus may have been missed. Studies 
have demonstrated cancer presence at subsequent biopsy in over 40% of cases49.  
 
Figure 1.7 Photomicrograph of atypical small acinar proliferation   
1.2.6 Adenocarcinoma of the Prostate 
Prostate adenocarcinoma (CaP) is an invasive malignant epithelial tumour consisting of 
secretory cells. The epidemiology and relevant clinical aspects of the disease will be 
outlined later in this thesis. Macroscopically on section grossly evident tumours appear 
firm and solid. Tumours usually extend microscopically beyond their macroscopic 
border. Subtle tumours may be recognised by structural asymmetry expanding and 
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obscuring boundaries of prostate zones. Anterior and apical tumours may be difficult to 
identify because of mixed stromal and nodular hyperplasia50. 
Microscopically, adenocarcinomas of the prostate range from well differentiated 
(difficult to distinguish from benign prostate glands) to poorly differentiated tumours 
(which may be devoid of features of prostatic origin). Common to virtually all cancers 
is the absence of a basal cell layer. Identification of basal cell absence may be difficult 
as certain cancers will have cells that mimic basal cells, therefore the use of special 
stains may be necessary to determine basal cell presence.  
When studying prostate tissue to determine whether cancer is present histopathologists 
focus on gland architectural, nuclear, cytoplasmic and intraluminal features in addition 
to searching for malignant specific features. Adenocarcinoma of the prostate is not 
recognised to elicit a stromal response therefore the stroma is not considered useful in 
prostate cancer diagnosis. 
Architectural features: Benign prostatic glands generally maintain a degree of order and 
are evenly dispersed. In contrast adenocarcinoma glands grow in a haphazard fashion. 
Features of infiltration include glands irregularly separated from each other by bundles 
of smooth muscle and the presence of small atypical glands situated between larger 
benign glands. More obvious features of malignancy are evident when there is loss of 
gland differentiation with the formation of cribriform structures, fused glands and 
poorly formed glands. Undifferentiated tumours may be composed of solid sheets, cords 
of cells or isolated individual cells. These above features are key components of the 
Gleason grading system (described in the next section). 
Nuclear features: The extent of nuclear atypia typically correlates with the architectural 
degree of differentiation. Nuclear enlargement with prominent nucleoli is a common 
feature in cancer cells but not diagnostic in isolation. In high grade cancer nuclear 
pleomorphism and mitotic figures may be seen. 
Cytoplasmic features: Prostate cancer glands tend to have a sharp luminal border in 
contrast with benign glands. Although cytoplasmic features of low grade prostate cancer 
glands are often not distinctive; tumour glands may have amphophilic cytoplasm. The 
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cytoplasm in all grades of prostate cancer generally lacks lipofuscin which is present in 
some benign prostate glands51.  
Intraluminal features: Crystalloids, eosinophilic crystal like structures may be seen 
frequently in low grade prostate cancer52. These structures may also be seen in benign 
glands but less frequently. Intraluminal pink acellular dense secretions or blue tinged 
mucinous secretions are findings seen preferentially in cancer53. In contrast corpora 
amylacea are common in benign glands and rarely seen in prostate cancer52.  
Malignant specific features: Perineural invasion, mucinous fibroplasia and 
glomerulations have not been described in benign tissue and are diagnostic of prostate 
cancer. Perineural invasion describes the presence of cancer cells circumferentially 
within the perineural space. Mucinous fibroplasia describes loose fibrous tissue with an 
ingrowth of fibroblasts. Glomerulations refers to gland with a cribriform pattern that is 
not transluminal. The cribriform structure may attach to only one edge of the gland thus 
resembling a glomerulus. 
1.2.7 The Gleason Grading System 
The Gleason grading system, named after Donald F Gleason, is the most widely used 
histopathological grading system for adenocarcinoma of the prostate. It was 
recommended by the World Health Organisation at a consensus conference in 199354. 
The Gleason grading system is based on glandular architecture; nuclear atypia is not 
evaluated55. Although other systems adopted nuclear atypia in their grading systems 
there has been no evidence that this added to the prognostic information obtained from 
glandular morphology56. The Gleason grading system describes five histological 
patterns or grades ranging from well differentiated to poorly differentiated (illustrated in 
figures 1.8-1.12, table 1.1). Prostate cancer is heterogeneous so more than one pattern 
may exist within a specimen. The most prevalent pattern and the second most prevalent 
pattern are combined to obtain a Gleason score between 2 and 10. Although the original 
classification did not account for patterns occupying less than 5% of the tumour or 
tertiary patterns, it is now recommended that the worst grade present should also be 
reported irrespective of its percentage present in radical prostatectomy specimens, 
because its presence is associated with a poorer prognosis57. In radical prostatectomy 
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specimens a higher Gleason pattern is reported as a tertiary grade if it occupies <5% of 
the tumour. In core biopsies the highest Gleason pattern is incorporated in the Gleason 
score irrespective of its percentage (higher Gleason grade is not applicable to core 
biopsies under current recommendations)58. Crush artefacts and evidence of hormone 
and radiation treatments within samples should not be Gleason graded. 
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Figure 1.8 Original schematic of the Gleason system 55 
 
Gleason Grade Histological Criteria  Differentiation 
1 Single, separate, uniform glands closely 
packed, with definite edge 
2 Single, separate uniform glands loosely 
packed, with irregular edge 
3A Single, separate uniform glands, scattered 
3B Single, separate, very small glands, scattered 
3C Papillary/cribriform masses, smoothly 
circumscribed 
4A Fused glands, raggedly infiltrating 
4B Same, with large pale cells (“hypernephroid”) 
5A Almost solid, rounded masses, necrosis 
(“comedocarcinoma”) 
5B Anaplastic, raggedly infiltrating 
Well differentiated 
 
 
 
 
 
 
 
 
Poorly differentiated 
Table 1.1 The histological criteria of Gleason 1-5 in the original wording55 
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Figure 1.9 Photomicrograph of Gleason pattern 2  
 
Figure 1.10 Photomicrograph of Gleason pattern 3 
 
Figure 1.11 Photomicrograph of Gleason pattern 4 
 
Figure 1.12 Photomicrograph of Gleason pattern 5 
1.2.8 Current Additional Cancer Molecular Profiling Techniques 
 
Immunohistochemistry currently plays a significant role in determining the presence of 
prostate cancer in samples which are difficult to classify; most commonly prostatic 
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biopsies. High molecular weight basal cell-specific cytokeratin, preferentially stains 
basal cells, confirmation of the presence of basal cells presence or absence is useful in 
the diagnosis of small acinar carcinoma59. Prostate specific markers such as PSA and 
PAP have limited role in identifying prostate tumours because antibodies of one or both 
are acknowledged to be present in both primary and secondary lesions, however benign 
glands may also be positive for these markers59. Neuroendocrine markers when used in 
well prepared prostate tissue are focally expressed in many adenocarcinomas although 
their role in carcinoma is unknown. There are a plethora of papers on genetic alterations 
present in prostate cancer: some appear to be random while others seem to be 
consistently present. Examples of markers which are being investigated include the 
proliferation markers: Ki-67, MIB-1 and PCNA60,61.  However the role of all these 
markers as providers of predictive or prognostic information has been limited by the 
heterogeneity of prostate tissue and conflicting results.  
 
DNA micro array technology has been used to quantitatively elucidate genes expressed 
by prostate cancer cells. The role of these genes in carcinogenesis can be further 
explored using micro array technology in combination with more complex statistical 
methods. The aim is to identify genes which could act as biomarkers for prostate cancer. 
However as one recently attempted meta-analysis of several microarray experiments has 
shown the comparison of genes from cells obtained from different laboratories is 
difficult because there are differences in preparation and experimental conditions62. 
Micro array technology has recently been used in combination with FTIR; this is 
discussed later in section 1.6.7. 
1.2.9 Limitations of Conventional Histopathology 
Prostate cancer diagnosis is dependent on obtaining prostate tissue specimens with the 
disease present. However because prostate cancers are often multifocal and 
heterogeneous in pathology, even if prostate biopsy targeting protocols are adhered to, 
negative biopsies do not exclude the possibility of prostate cancer. Similarly, positive 
biopsies may not contain or reflect the degree and severity of prostate cancer present 
within the prostate. 
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Pathology is the gold standard for prostate cancer diagnosis. Prostate core biopsies may 
contain limited carcinoma within the sample and cancer diagnoses can then be missed 
on account of human error. Several studies have demonstrated that when prostate cancer 
is present there is inter-observer variation in applying Gleason grade3,4,5,6,63. Uro-
pathologists achieve the best reproducibility in their assessment of Gleason grade 
(kappa 0.61-0.80). General pathologists have moderate inter-observer agreement (kappa 
0.41-0.60). These studies illustrate that variability in interpretation is a global 
phenomena63,64, under diagnosis of Gleason grade is the main problem. Specific 
difficulties include recognising the border areas between Gleason patterns and that 
microscopic foci of carcinoma do not necessarily represent low grade carcinoma. A 
criticism of these studies might be that they contain a small number of observers, 
however this is likely to represent current practice. Significant improvements in 
Gleason grading have been achieved by online tutorials65,66 and regular refresher 
courses may be beneficial for non specialist pathologists covering a urological 
workload. Egevad et al. performed an international survey of current Gleason grade 
practice and found that 77 genitourinary pathologists demonstrated varying opinions on 
the actual criteria themselves64. The subjectivity in interpretation of the Gleason grade is 
a concern because the pathological assessment guides treatment. Innovations to make 
pathological analysis more robust would be welcomed by all involved in ensuring the 
delivery of high quality patient care. 
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1.3 Prostate Cancer Epidemiology 
1.3.1 International Prostate Cancer Epidemiology 
Worldwide 670,000 men were diagnosed with prostate cancer in 2002, accounting for 
one in nine of all new male cancers. Three quarters of new diagnoses are made in the 
developed world with the highest rates in North America and the lowest rates in Asia1. 
An ageing population, increased surgery for benign prostatic hyperplasia, increased 
health awareness and screening for prostate cancer using the Prostate Specific Antigen 
(PSA) blood test are thought to account for the increasing incidence of the disease67.  
1.3.2 United Kingdom Prostate Cancer Epidemiology 
In 2006, 35,515 new cases were diagnosed in the UK, accounting for 24% of all new 
male cancer diagnoses. The current lifetime risk of being diagnosed with prostate cancer 
is one in ten68. The majority of men found to have prostate cancer are diagnosed over 
the age of 65 with the largest number of cases diagnosed in those aged between 70 and 
7469,70,71,72. Post mortem studies estimate that 50% of men over 50 will have histological 
evidence of prostate cancer, this percentage rises to 80% by the age of 80. However 
only one in 26 (3.8%) will die of the disease73. McGregor et al determined that of 
patients with detectable prostate cancer that would prove lethal by the age of 85 only 
16% would actually die from prostate cancer, the rest would die from other causes74. 
This data may be interpreted to conclude that ‘men are more likely to die with rather 
than from prostate cancer’. 
There were 10,239 deaths from prostate cancer in the UK in 2007, accounting for 13% 
of male deaths69,71,75 . Prostate cancer remains second to lung cancer as the leading 
cause of male cancer death in the UK, a situation mirrored in worldwide statistics. 
Despite a dramatic rise in the incidence of prostate cancer over the last twenty years, 
mortality rates only rose marginally until 2003/2004. Rates have fallen slightly since 
2003 but it is not possible to elicit whether this is attributable to improved cancer 
treatments, changes in cancer registry coding76, the attribution of death to prostate 
cancer77 or the effects of PSA testing. This is illustrated in Figure 1.13. 
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Survival rates in the UK have improved over the last twenty years. The relative five 
year survival rate from prostate cancer for diagnoses made in 2000 - 2001 in England 
and Wales was 71% compared with 31% for men with diagnoses made between 1971 – 
197578,79.  
Interpretation of these trends is difficult however because the case mix of patients 
diagnosed has changed. The statistical anomaly called ‘Will Rodgers phenomenon’ is 
well documented and may account for improved patient survival from prostate cancer. 
Between 1992 and 2002, interpretation of the Gleason grading system was amended to 
stop the diagnosis of Gleason 2 adenocarcinoma of the prostate. The lowest Gleason 
grade allocated to prostate specimens became 3+3=6. This had the effect of causing 
migration in Gleason grade i.e. Gleason 2 disease became Gleason 3 and an associated 
tendency for pathologists to promote higher Gleason grades accordingly. Gleason grade 
and stage are used to produce standardised disease outcome data. Therefore if 
contemporary Gleason grades are higher, survival from prostate cancer by Gleason 
grade may not actually have changed over time. Thus what has been represented in 
survival trends is purely the reclassification of Gleason grade80. 
The recent emphasis on early prostate cancer detection has led to increasing numbers of 
young patients being diagnosed with early cancers. Although some improvement in 
survival will be due to early diagnosis and improved prostate cancer treatment,  
urologists are aware that increasing numbers of early cancers which may have been 
clinically insignificant may be being identified, thereby causing lead–time bias (earlier 
diagnosis of disease with no lengthening of life). 
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Figure 1.13 Age specific mortality rates, prostate cancer, UK, 1971-200781 
 
1.3.3 Aetiology of Prostate Cancer 
Increasing age73, family history82 and ethnicity83 are currently the only established risk 
factors for prostate cancer. Despite a keen interest in establishing potentially modifiable 
factors, no definitive evidence to support a change in treatment strategy exists. Diet84, 
lifestyle85,86 , endogenous hormones87, and medical conditions88 / interventions89,90 have 
been and continue to be investigated. The difficulty of performing such epidemiological 
studies is firstly the confounding multifactorial influences affecting the development of 
prostate cancer and secondly the fact that we are in a PSA era (the PSA test will be 
discussed in detail in the following section) and variable thresholds for performing the 
investigation means a PSA detection bias exists91. 
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1.4 Diagnostic Modalities of Prostate Cancer 
Prostate cancer may cause prostate gland enlargement leading men to present with 
symptoms, however localised prostate cancer is often asymptomatic. Men commonly 
present now for investigation of their prostate because of concerns raised by 
increasingly prominent public health campaigns about prostate cancer or because 
relatives, friends or celebrities have been diagnosed with the disease. This section 
describes current clinical diagnostic modalities and practice. 
1.4.1 Clinical Signs and Symptoms 
The majority of prostate cancers arise in the peripheral zone, therefore it is unusual that 
sufficient enlargement will occur in the PZ to cause urinary symptoms in the form of 
urinary frequency and difficulty in passing urine. Although transitional zone tumours 
and large PZ tumours may cause urinary outflow symptoms; it is likely that coexisting 
transitional zone enlargement secondary to hyperplasia contributes towards most men 
presenting for investigation in this way. Haematuria, haematospermia and perineal 
discomfort may also cause men to present for investigation.  
Locally advanced prostate cancer may present with all the above features in addition to 
pelvic pain, rectal bleeding, or renal failure secondary to ureteric obstruction. Malignant 
priapism and rectal obstruction are rarely seen possible presenting symptoms. 
Metastatic prostate cancer is often occult however activity at sites of spread may cause 
symptoms. Bone pain, pathological fractures or spinal cord compression may result 
from bone metastasis. Lymphadenopathy may cause lower limb swelling due to the 
blockage of lymph channels. Other presentations may occur due to the generalised 
systemic effects of malignancy. 
1.4.2 Digital Rectal Examination 
Digital rectal examination (DRE) is performed to assess the external contour of the 
prostate gland. Most prostate cancers originate in the peripheral zone and may be 
detected by DRE when the volume is 0.2ml or larger. An abnormal DRE is not specific 
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for cancer; both prostatitis and benign prostatic hypertrophy may cause an abnormal 
examination. The risk of a positive DRE turning out to be a prostate cancer is closely 
related to the PSA value: the higher the PSA value the more likely the DRE assessment 
will be positive. An abnormal DRE in the presence of a normal PSA, < 4.0ng/ml, has a 
30% chance of predicting a prostate cancer, for this reason DRE is a vital part of the 
diagnostic process92. DRE is also important for the clinical staging of disease as 
described in the next section. 
1.4.3 Prostate Specific Antigen 
Prostate specific antigen (PSA) was discovered in 1979 by Wang et al93. PSA is a 
kallikrein-like serine protease produced almost exclusively by the epithelial cells of the 
prostate and secreted into the ductal system. The normal mode of existence in serum is 
in complex with α-1-anti-chymotrypsin and α-2-macroglobulin, only a small percentage 
of serum PSA is in its free form. Serum PSA is determined by immunoassay techniques. 
Currently there are many different commercial kits but no common international 
standard exists94. Monoclonal antibodies have been designed to detect the free form of 
PSA, the complex of PSA and α-1-anti-chymotrypsin and the total PSA. 
Total PSA has been found to correlate well with advancing age and it has been 
advocated that these values are taken into account with respect to PSA related 
diagnostic strategies95. There is no universally accepted cut off point or upper limit of a 
normal PSA; values over an arbitrary cut off point of 4.0ng/ml are inferred to be 
abnormal in manufacturers’ reference ranges; however many men may harbour prostate 
cancer with a low serum PSA. This is illustrated in table 1.2 which shows the rates of 
prostate cancer in relation to serum PSA, in men deemed to have normal PSA values, in 
the placebo arm of a US prevention study96.  
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PSA level ng/ml Risk of Prostate Cancer (%) 
0-0.5 6.6 
0.6-1 10.1 
1.1-2 17 
2.1-3 23.9 
3.1-4 26.9 
Table 1.2 The risk of prostate cancer in relation to low PSA values96 
In the decade that followed PSA’s discovery, studies demonstrated that PSA could be 
detected in human serum and that there was a positive correlation between an elevated 
serum PSA and prostate tumour volume and stage97,98. Based on the assumption that 
most adenocarcinomas secrete more PSA than normal or hyperplastic glands the PSA 
blood test gained widespread acceptance as a prostate cancer screening tool in clinical 
practice in the developed world. The original author Stamey, who identified the link 
between blood PSA levels and prostate cancer, recently questioned the validity of PSA 
in its current role. He presented evidence to support a significant body of opinion in the 
urological community that the majority of cancers picked up by PSA screening are 
clinically insignificant99. PSA is useful to detect recurrence and monitor response in 
patients with prostate cancer who have undergone therapy. The limitations of the PSA 
test are primarily that it is organ specific but not cancer specific and therefore may be 
raised in benign pathologies including urinary tract infection, BPH and prostatitis. PSA 
is a poor predictor of prostate cancer volume and severity especially at low levels 
(<10ng/ml) where the PSA value more accurately reflects the size of the gland99. 
Intertumoural variation in PSA secretion also limits the diagnostic sensitivity of the test 
as certain subtypes of prostate cancer for example small cell neuroendocrine carcinoma 
are associated with low PSA concentrations100. 
Improving the characteristics modifications of the PSA has been considered; PSA 
velocity (rate of change over time) and PSA density (PSA ratio to prostate volume) 
have not demonstrated a greater value than PSA alone in prostate cancer diagnosis96,101. 
Free PSA, the free form of PSA, is present in a greater proportion of men without 
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cancer. The concept of the free / total PSA ratio (f/t PSA) has been extensively 
investigated to attempt to differentiate between BPH and prostate cancer in men with 
PSA levels between 4 and 10ng/ml and a negative DRE. In a prospective multicentre 
trial, prostate cancer was found in 56% of men with a f/t PSA ratio of <0.10 but in 8% 
of men with a f/t PSA > 0.25102. Free PSA is however unstable at room temperature and 
at 4°C and assays are not standardised as there are many inactive isoforms of free PSA 
including pro-PSA and BPSA, therefore caution in clinical application of these results is 
necessary.   
1.4.4 Prostate Specific Antigen and Prostate Cancer Screening 
Wilson and Jungner established the criteria that should be upheld in a gold standard 
screening assessment103. Prostate cancer screening and specifically the PSA test do not 
fulfil most of these criteria. Controversy exists about whether with changing public 
healthcare expectations and advances in technology the Wilson and Jungner screening 
criteria should be modified. In the case of prostate cancer the debate ranges: from the 
advocates who say the relatively inexpensive test detects clinically significant disease, 
to the opponents of screening who highlight the low specificity, over diagnosis and 
morbidity and cost of further investigation and treatment of prostate cancer. Two large 
population based randomized trials were designed to evaluate the efficacy of screening 
using DRE and the PSA test and have recently reported their early findings.  
The Prostate, Lung, Colorectal and Ovary trial (PLCO) randomly assigned 76,693 men 
in the United States to receive either annual screening or usual care. The subjects were 
aged between 55 and 74 and a PSA of over 4.0ng/ml was deemed to be positive for 
prostate cancer. After seven to ten years of follow up although the screened group was 
associated with a 22% increase in the rate of prostate cancer detection and good 
compliance there was no difference in prostate cancer mortality between the two 
groups104. One of the limitations of this study is that in US healthcare is privately 
funded and the majority of men within this trial are likely to already have had a serum 
PSA prior to inclusion in the trial105. Men with significant tumours who were young and 
may have benefited from screening would not have been entered into the trial as they 
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would have been undergoing treatment. This may account for the lack of survival 
benefit of screening. 
The European Randomized Study of Screening for Prostate Cancer (ERSPC) 
randomized 182,000 men between the ages of 50 and 74 years to PSA screening at an 
average of once every four years and a control group receiving no screening. During a 
median follow up of nine years, this study found a higher proportion of prostate cancers 
in the screened group but concluded the rate of death from prostate cancer was reduced 
by 20%. However they also highlighted 1410 men would need to be screened and 48 
additional cases of prostate cancer would have to be treated to prevent one death from 
prostate cancer106.  The ERSPC also has limitations: the study was conducted in several 
different countries and therefore variability regarding the men included and strategies 
for screening and follow up occurred. The PSA threshold for prostate biopsy was also 
lower at 3.0ng/ml when compared to the PLCO trial. 
Further analyses of these trials will undoubtedly be reported in the future however both 
highlight the risks of over diagnosis and over treatment associated with PSA screening. 
Clinicians will evaluate the data in different ways but a shared decision making 
approach to PSA screening is currently more appropriate than ever. 
1.4.5 Biomarkers for Prostate Cancer Detection 
Biomarkers which can both identify prostate cancer and accurately differentiate indolent 
from aggressive cancers are being investigated. A brief summary of emerging markers 
is described below. 
Prostate Cancer Gene 3 (PCA3) is a biomarker that is being used in clinical practice 
albeit only in certain institutions in the United Kingdom. PCA3 is present in urine, 
expressed prostatic secretions, semen and prostate tissue. The marker usually is 
measured in urine after DRE and prostatic massage which allows shedding of prostate 
epithelial cells. The marker is evaluated using reverse transcriptase polymerase chain 
reaction (PCR). PCA3 is over expressed in 95% of prostate cancers and in studies to 
date a sensitivity and specificity of 66% and 89% respectively have been achieved. The 
sensitivity of PCA3 is increased in the subgroup of patients with a PSA less than 
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4.0ng/ml107,108. Although the results to date have been encouraging there is need for 
further refinement of this test before it would replace PSA in routine practice for 
screening. Currently the investigation is particularly useful for determining who to re-
biopsy in men with an elevated PSA level and no prostate cancer on initial biopsy, men 
who are found to have cancer with normal PSA levels, men with PSA levels elevated 
secondary to prostatitis and in active surveillance of men with suspected multifocal 
disease.   
Translocation or gene fusion markers are genes found in cancerous tissue, which are not 
expressed in benign tissue. ERG and ETV1 are two examples of genes that have been 
identified to be present specifically in prostate cancer109. 
Proteonomics is the large scale study of proteins. Proteins are the end product of gene 
expression and are the functional mediators of cellular changes in cancer. In the search 
for protein biomarkers, surface enhanced laser desorption/ionization time of flight 
(SELDI-TOF) and matrix assisted laser desorption/ionization-TOF mass spectrometry 
are currently the most common techniques used however reproducibility is currently a 
concern. Trials to establish the reproducibility of the technique have been 
commenced110,111.  
Autoantibodies directed against prostate cancer tumour specific antigens have also been 
discovered using high throughput proteonomic techniques. Multiple autoantibody 
signatures have been identified in serum and when used as a panel together have 
demonstrated a better specificity and sensitivity performance for prostate cancer 
detection than serum PSA112. However further studies are required in to develop this 
technology.  
Prostate stem cell antigen (PSCA) is a prostate specific glycoprotein that is expressed 
on surface of prostate cancer cells. This can be detected by immunohistochemistry and 
PSCA RNA in blood. Increased PSCA expression has been related to increased prostate 
cancer risk113,114. 
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Prostate specific proteins GSTP-1115,116, EPCA117, HK2118, Hepsin119 have all 
demonstrated promise as possible biomarkers however refinements in detection and 
further study is required to confirm their usefulness. 
High throughput technologies, like genomic microarrays, have facilitated biomarker 
discovery in different specimens including serum, urine and prostatic tissue however 
rigorous scientific investigation is necessary before any are introduced into routine 
practice. Researchers and clinicians are mindful of the legacy of the PSA test; which 
took more than 10 years to reach clinical practice after its discovery but took 
approximately the same amount of time to understand its limitations.       
1.4.6 Transrectal Ultrasonography and Prostatic Biopsies 
Transrectal ultrasonography (TRUS) enables the operator to measure gland volume and 
delineate obvious focal lesions. Although some prostate cancers may be visualised as a 
hypoechoic lesion in the peripheral zone the appearance is non specific120. The primary 
application remains the image guidance of transrectal or perineal biopsies. TRUS 
guided 18G core biopsy has become the standard way to obtain prostate tissue for 
pathological examination in patients suspected of having prostate cancer. Multiple cores 
may be taken with low complications if antibiotic prophylaxis is used121,122. Sampling 
sites should be as far posterior and lateral in the gland as possible. At least eight biopsy 
cores should be taken, more than twelve cores are not significantly more conclusive123. 
The British Prostate Testing for Cancer and Treatment Study has recommended ten core 
biopsies124. Current indications for re-biopsy are rising or persistently high PSA, a 
suspicious DRE, or findings of ASAP or extensive PIN125. The quantification of the 
amount of cancer on the needle biopsy, number of positive cores and core location give 
clinicians valuable information about individual tumour characteristics126. 
1.4.7 Magnetic Resonance Imaging, Computed Tomography and Nuclear Medicine 
Cross sectional imaging techniques such as magnetic resonance imaging (MRI) and 
computed tomography (CT) are used for disease staging of patients with prostate cancer 
(see section 1.4.6). Studies in the past have demonstrated low sensitivity to detect 
prostate cancer. MRI spectroscopy is being evaluated in a diagnostic role however its 
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ultimate role is also likely to be in staging prostate cancer (see section 1.7.2) and is 
currently predominantly a research technique. Radionucleotide bone scans provide a 
sensitive method for diagnosing bone metastases and play an important role in prostate 
cancer staging. Elderly patients or patients with multiple co-morbidities who present 
with a significantly elevated PSA and abnormal DRE may only have a bone scan to 
confirm their diagnosis. If the bone scan demonstrates bone metastases then the 
assumption may be made that prostate cancer is the primary however this is not routine 
clinical practice and a histological diagnosis is preferred. 
1.4.8 TNM Staging of the Prostate 
Staging is a method of describing the extent of local and distant spread of any tumour. 
Staging may be either clinical (based on examination and radiological findings) or 
pathological (based on pathology specimen analysis). Staging is important in clinical 
practice because it enables an assessment of prognosis and thus guides patient 
management. The Tumour Node Metastases (TNM) staging system is adopted by most 
urologists for prostate cancer127. T-stage describes the extent of local spread and is 
assessed by DRE and imaging. N-stage is assessed by imaging or biopsy of suspicious 
lymph nodes. M-stage is assessed by examination, imaging and biochemical 
investigations. The definitions of each stage are described in Table 1.3.
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 T – Primary tumour 
Tx Primary tumour cannot be assessed 
T0 Evidence of primary tumour 
T1 Clinically inapparent tumour not visible by imaging 
T1a Tumour incidental histological finding 5% or less of tissue resected 
T1b Tumour incidental histological finding in more than 5% of tissue resected 
T1c Tumour identified by needle biopsy (e.g. because of elevated prostate 
specific antigen [PSA] level) 
T2 Tumour confined within the prostate 
T2a Tumour involves one half of one lobe or less 
T2b Tumour involves more than half of one lobe, but not both lobes 
T2c Tumour involves both lobes 
T3 Tumour extends through the prostatic capsule 
T3a Extracapsular extension (unilateral or bilateral) including microscopic 
bladder neck involvement 
T3b Tumour invades the seminal vesicle(s)  
T4 Tumour is fixed or invades adjacent structures other than seminal vesicles: 
external sphincter, rectum, levator muscles, and/or pelvic wall 
N – Regional lymph nodes 
Nx Regional lymph nodes cannot assessed 
N0 No regional lymph node metastasis 
N1 Regional lymph node metastasis 
M – Distant metastasis 
Mx Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1a Non-regional lymph node(s) 
M1b Bone(s) 
M1c Other site(s) 
Table 1.3 TNM (2009) staging of adenocarcinoma of the prostate127 
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1.5 Management of Patients with Prostate Cancer 
The studies in this thesis focus on prostate cancer diagnosis. The management of 
patients with prostate cancer is a huge subject area; for the purpose of understanding 
some of the treatment options available for patients with prostate cancer, a brief 
discussion of treatment modalities follows.    
1.5.1 Management of Patients with Localised Prostate Cancer 
Men diagnosed with prostate cancer who have no obvious evidence of spread of their 
disease outside of the prostate are eligible for all radical (curative) treatment options. 
The National Institute for Health and Clinical Excellence (NICE) has recently published 
clear guidelines about how patients should be risk stratified and managed. This is 
illustrated in table 1.4. 
Watchful Waiting: This refers to the avoidance of treatment unless there is disease 
progression. Those who progress may be offered hormone therapy or palliation. This is 
usually offered to older men or those with multiple co-morbidities who are more likely 
to die from something other than prostate cancer. 
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Low-risk men (PSA 
≤ 10 ng/ml and Gleason 
score ≤ 6 and T1-T2a) 
 
Intermediate risk men 
(PSA 10-20 ng/ml or 
Gleason score 7 or T2b-2c) 
 
High-risk men 
(PSA ≥20 ng/ml or 
Gleason score ≥8 or 
T3-T4) 
 
Watchful waiting    
 
Active surveillance 9  X 
 
Brachytherapy 
 
  X 
 
Prostatectomy 
 
 9 9 
 
Radiotherapy 
 
 9 9 
 
Cryotherapy 
 
X* X* X* 
 
HIFU 
 
X* X* X* 
 
 
 
 
  
 
 
 
 
 
Table 1.4 NICE guidance on the management of men with localised prostate cancer128
9 Preferred treatment 
 Treatment option 
X Not recommended 
X* Not recommended other than in the context of clinical trials 
• Should be treatment of choice 
in low-risk men who are 
suitable for radical treatment 
• Include at least 1 re-biopsy 
• If evidence of disease 
progression men should be 
offered radical treatment 
• Use 3D conformal 
radiotherapy 
• Minimum dose 74 
Gy (maximum 2 Gy 
per fraction) 
 
 35
Active Surveillance: Active surveillance aims to avoid the unnecessary treatment of 
early prostate cancers which may prove to be indolent. These men are kept under 
regular surveillance using the PSA blood test, DRE and if appropriate repeat prostatic 
biopsy. If their disease demonstrates any evidence of early progression the patients are 
offered radical treatment. This treatment has recently been advocated to avoid inflicting 
unnecessary morbidity on patients who have had a low risk early cancer diagnosed. 
Radical Prostatectomy: This is the surgical removal of the entire prostate gland and 
seminal vesicles. The approach can be open via either the retropubic or perineal 
approach or use the minimally invasive techniques of laparoscopy or robotic surgery. 
The risks of surgery are significant and include incontinence, erectile dysfunction and 
the possibility of surgically positive margins (failure to remove all cancer cells). 
External beam Radiotherapy: This is usually preceded by hormonal treatments such as 
Zoladex (goserelin) injections. Doses are delivered in fractions over a four to eight week 
period. Radiotherapy also has significant associated risks: disease recurrence, altered 
urinary and bowel activity and erectile dysfunction. Adjuvant hormone therapy may be 
continued post treatment. 
Brachytherapy: This is a form of radiotherapy in which the radiation is given through 
radioactive sources either permanently implanted seeds (low dose) or temporarily 
inserted wires (high dose). Brachytherapy may not be possible in a large prostate gland. 
Relative contraindications include men with bladder outflow obstruction symptoms. 
Brachytherapy shares similar risks with radiotherapy. 
HIFU and Cryotherapy: These techniques use technology to either heat or freeze the 
prostate. The objective is destruction of the prostate cancer; these techniques are 
currently in the early phases of rigorous scientific investigation. 
1.5.2 Management of Patients with Advanced Prostate Cancer 
The mainstay of treatment for patients who have metastatic prostate cancer is hormone 
therapy. Cytotoxic chemotherapy may be considered in patients with good performance 
status should the prostate cancer become androgen independent. Palliative care 
approaches are the mainstay of treatment in the terminal phase of the illness. 
1.5.3 The Practical Challenges of Prostate Cancer in Clinical Practice 
PSA screening irrespective of the evidence base to support it is for the moment 
commonplace in clinical practice. The PSA test has undoubtedly contributed not only to 
the increased incidence of known prostate cancer129, but also to the increased number of 
men presenting for urological review and prostate biopsy as a result of a raised PSA. 
Over diagnosis of prostate cancer is an accepted consequence of current practice. The 
concept of active surveillance was introduced to counter the unnecessary treatment of 
clinically insignificant prostate tumours130. Unfortunately though we can attribute 
tumour risk by analysis of its characteristics we do not yet have a test that can 
accurately differentiate clinically aggressive (significant) tumours from those that will 
be clinically insignificant. For this reason men diagnosed with localised prostate cancer 
have to deal with uncertainty and anxiety in addition to potential morbidity whether 
they have active surveillance or active intervention. There is a need for a marker to 
determine severity of disease. 
The management and follow up of patients with both suspected and confirmed prostate 
cancer accounts for a significant proportion of Urology and Oncology departments’ 
workloads and budgets. The publication of the NHS cancer plan in 2000131 has added 
external pressure from the Department of Health on minimising patients’ waiting time 
before they are seen in clinic. Currently patients in the UK with suspected prostate 
cancer should be seen within 2 weeks of referral132 and should not have to wait longer 
than 18 weeks from GP referral to treatment133. The burden on the histopathology 
service has increased exponentially as a result of the number of biopsies resulting from 
abnormal PSA tests. Pathology manpower shortages are rarely reported however 
anecdotally their existence is recognised and evident in clinical practice134. Novel 
approaches to speed up the diagnostic pathway will benefit both clinicians and their 
patients. 
The cost burden of prostate cancer treatment and management is significant. Wilson et 
al. compared the cost of prostate cancer treatments over 5.5 years in 4553 newly 
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diagnosed patients in America.  The individual cost in the first six months including 
treatment and follow up ranged from 2586 dollars (for a patient undergoing watchful 
waiting) to 24,204 dollars (for a patient undergoing external beam radiation). The 
average annual cost of follow up after the first year was 7740 dollars135. Cost savings in 
the current recession are necessary and prostate cancer management is no exception. 
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1.6 Fourier Transform Infrared Spectroscopy 
Isaac Newton (1642-1727) discovered that white light directed at a prism could be 
separated into its component colours, a spectrum, in 1704. Newton’s law of the 
composition of light was published in Optiks in 1704 and formed the origin of the 
science of spectroscopy – the study of spectra.  
Bunsen and Kirchoff invented the first spectroscope capable of analysing chemical 
composition in 1859. This device comprised a prism with a combination of lens and 
slits. Technological advances and refinements of the integral components have led to 
modern day spectrometers.  The work in this thesis concentrates on infrared 
spectroscopy and the theory which follows is relevant to this field. 
1.6.1 The Theory of Molecular Spectroscopy 
Electromagnetic radiation, of which visible light forms a small part, is composed of a 
magnetic and electric field positioned perpendicular to each other. The propagation of 
light from a source through space can be considered as a sinusoidal wave as illustrated 
in figure 1.14. Light will travel in a straight line unless interrupted by molecules or 
matter in its path. When the electric component of light interacts with matter it may 
absorbed, scattered or pass through it, producing a spectrum. Molecular spectroscopy is 
the quantitative and qualitative analysis of the spectra produced by this interaction. 
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Time 
A
π/ω 2π/ω 
Wavelength (λ) Displacement 
 
Figure 1.14 The Sinusoidal path of light through space 
The above figure illustrates a harmonic wave: this has the same properties of a sine 
wave: 
y=A sin θ   (1) 
For any point travelling along the wave: y is the displacement, A is the maximum value 
of the displacement and θ is an angle varying between 0 and 360° (or 0 and 2π radians) 
dependent upon its position on the curve. 
If it is considered that a point travels with uniform velocity ω rad s-1 then the time taken 
to complete an angle is equivalent to: 
θ= ωt    (2) 
From this it can be inferred that the displacement described in equation (1) can also be 
described as below: 
y= A sin θ = A sin ωt   (3) 
The time through a complete cycle is therefore: 
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2π/ω     (4) 
The number of times the cycle repeats itself in 1 second (s) is referred to as the 
frequency, v, the SI unit is Hertz (Hz) with the dimensions s-1: 
v=ω/2π    (5) 
From this, the following equation of wave motion can be written: 
y= A sin ωt = A sin 2πvt  (6) 
When considering a travelling wave, the distance variation of the displacement is 
important. The following distance-time relationship is essential for this where x is the 
distance covered in time t at speed c: 
x=ct     (7) 
Combining equations (6) and (7): 
y= A sin 2πvt = A sin (2πvx/c)  (8) 
The distance travelled by the wave in a complete cycle is referred to as its wavelength, 
λ. If velocity equals c metres per second and there are v cycles per second, there will be 
v waves in c metres or: 
vλ = c from which we can say λ = c/v metres (9) 
Combining equations (8) and (9): 
y= A sin (2πx/λ)   (10) 
In infrared spectroscopy the wavelength is usually given in micrometers (μm) also 
sometimes described as microns (1μm = 10-6m).  Electromagnetic radiation can also be 
characterised in terms of wavenumber ύ. This is the reciprocal of the wavelength and 
expressed in centimetres: 
ύ = 1 / λ cm-1    (11) 
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and hence: 
y = A sin 2πύx   (12) 
Wavenumber is the number of complete waves or cycles in each centimetre length of 
radiation. Due to the definition being based on centimetres rather than metres, 
wavenumber is not an official SI unit however it is still used for the discussion of 
infrared spectra.    
The current concept of how light interacts with matter was realised in 1900 by Max 
Planck. A molecule in space may have many sorts of energy: vibrational energy 
resulting from the periodic displacement of its atoms from equilibrium, and electronic 
energy due to the fact that electrons associated with each atom are in constant motion. 
Electrons in atoms or molecules exist in discrete energy levels: this energy is referred to 
as quantized. In the same way molecules in different vibrational states are quantized. To 
move from one level to another requires a sudden jump requiring a finite amount of 
energy. This is illustrated in figure 1.15 below. Transitions may take place between 
energy levels E1 and E2 (the suffixes 1 and 2 used to describe energy levels in fact 
represent quantum numbers). In order to move between the levels a specific amount of 
energy must be emitted or absorbed by the system, ∆E. 
E2
∆E 
E1
 
Figure 1.15 Quantized energy states of a molecule 
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Planck described that electromagnetic radiation could be emitted or absorbed during a 
transition between levels. The frequency of the radiation: 
v = ∆E/h Hz    (13) 
and therefore: 
∆E = hv    (14) 
where E is expressed as a joule and h is a universal constant – Planck’s constant. 
This is practically important in molecular spectroscopy because if we take a molecule in 
state E1 and direct a beam of electromagnetic radiation of one frequency v (i.e. 
monochromatic radiation) onto it, where v = ∆E/h, energy will be absorbed from the 
beam and the molecule will jump to state E2. If a detector was placed to collect the 
radiation after its interaction with the molecule the intensity of the beam will have 
decreased. To expand on this concept, if a beam containing a wide range of frequencies 
is directed on to a molecule, with a detector to collect the radiation, the detector will 
show that energy has been absorbed only from that frequency where v = ∆E/h, all the 
other frequencies will be unchanged in intensity. This is how an absorption spectrum is 
produced. An emission spectrum would be produced if the molecule reverted from state 
E2 to E1.  
The actual energy differences between the levels are very small and are expressed as 
joules per molecule. Planck’s constant has the value: 
h = 6.63 x 10 -34 joules s molecule -1 
Often if interested only in the total energy involved when a gram of a substance changes 
state, spectroscopists may multiply by the Avogadro number (N=6.02 x 1023).  
The electromagnetic spectrum is illustrated in figure 1.15. The molecular processes 
associated with each region are different. The infrared portion of the spectrum is 
between the 100μm and 1μm wavelength. Infrared light passes easily through air and is 
one of the most valuable spectroscopic regions. The infrared region can be subdivided 
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into near, mid and far infrared. Most Fourier Transform spectrometers and 
spectroscopists operate in the mid infrared region. 
 
Figure 1.16 The Electromagnetic Spectrum 
The concept of how a spectrum is represented can be likened to a conventional X-Ray. 
If radiation is shone at the plate and nothing is in between the radiation and the plate, 
the plate will show an even blackening over the frequencies emitted by the radiation 
source. If a part of the body is placed between the radiation and the plate over the 
frequencies where radiation is absorbed the blackening will only be present at the 
frequencies where radiation has not been absorbed. Where absorption has taken place an 
interaction between radiation and molecules will have occurred and be represented by 
absorption lines. The intensity of the absorption lines will be dependent on the degree of 
absorption that has occurred at a specific frequency, different body structures for 
example bone and soft tissue will absorb to different degrees. This represents the 
contrast between structures on an X-Ray.  
The other important concept is that when radiation is absorbed, to enable a transition a 
sample (material under investigation) will continue to demonstrate an absorption 
spectrum for as long as it is irradiated. There is a finite amount of sample, therefore the 
sample although seemingly capable of absorbing an infinite amount of energy must be 
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getting rid of the energy absorbed. Some of the energy will be lost as kinetic energy and 
the sample will become warmer. Another mechanism will be losing the energy as 
electromagnetic radiation as molecules revert to their ground or resting state. This 
energy is re-emitted in a random direction, essentially scattered and a negligible 
proportion reaches the detector in practice which is why it does not affect the absorption 
spectrum.   
1.6.2 Infrared Spectroscopy 
Infrared spectroscopy is possible because molecules vibrate when they interact with 
radiation. If a molecule is considered in its resting stable energy state it will have a 
number of degrees of freedom: the potential to change position in space and rotation. If 
N = the number of atoms in the molecule then the number of degrees of freedom if the 
molecule is non linear is:  3N-6 (3 translational and 3 rotational) and if the molecule 
linear: 3N-5 (3 translational and 2 rotational). To illustrate if we take oxygen (O2), 
shown below in figure 1.17, which is a diatomic linear molecule, only one stretch 
vibration exists ((3x2)-5 = 1).  
 
Figure 1.17 Vibrational stretch of oxygen 
 
If we take a non linear molecule such as water (H2O) it has ((3x3) – 6) = 3 degrees of 
freedom. This is illustrated in Figure 1.18. 
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Asymmetrical stretch       Symmetrical stretch  Deformation 
Figure 1.18 Vibrational modes of water 
Infrared spectroscopy is an absorption spectroscopy. If incident infrared radiation 
corresponds to the appropriate ∆E (previously described in section 1.5.1) to cause a 
molecule to be promoted to a higher energy state it will be absorbed. The change in 
energy state is represented in infrared spectroscopy by a change in vibrational mode. 
The key to a substance being infrared active is that there must be a change in dipole 
moment with the vibrational change. This change in moment is stimulated by the 
electrical field interaction with the molecules’ dipole moment and may be either parallel 
or perpendicular to the line of symmetry axis. 
If we consider carbon dioxide (CO2) for example as a linear molecule with essentially 
one degree of freedom in the mode of vibration ‘symmetric stretch’; the molecule is 
symmetrically stretched and compressed with both CO bonds changing simultaneously. 
The dipole moment or net charge remains unchanged throughout and therefore this 
vibration is infrared inactive (illustrated in Figure 1.19). 
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 compressed 
normal 
stretched 
Oδ- Oδ- C 2δ+ 
Oδ- Oδ- C 2δ+ 
Oδ- Oδ- C 2δ+ 
Figure 1.19 Symmetrical stretching of Carbon Dioxide molecule 
However if CO2 is considered in the linear asymmetric stretch mode as shown in Figure 
1.20, there is a periodic alteration in dipole moment (illustrated with red arrow) and this 
vibration is infrared active. 
C 2δ+ 
Oδ- 
Oδ- 
C 2δ+ 
Oδ- 
Oδ- 
C 2δ+ 
Oδ- 
Oδ- 
C 2δ+ 
Oδ- 
Oδ- 
C 2δ+ 
Oδ- 
Oδ- 
 
Figure 1.20 Asymmetric stretching of carbon dioxide with change in dipole 
illustrated 
A complex molecule will have a large number of vibrational modes involving the whole 
molecule.  Infrared spectroscopists have defined frequencies at which characteristic 
bond vibrations will occur when known chemical groups are present within a sample. 
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Certain bonds will absorb at the same wavelength range regardless of the structure of 
the molecule. For example the C=O stretch of a carbonyl group occurs at approximately 
1700cm-1 in ketones, aldehydes and carboxylic acids. This is the principle upon which 
infrared spectroscopy can be used for chemical identification. Spectroscopists refer to 
the fingerprint region of a spectrum (<1500cm-1) which is unique for a molecule and the 
functional group region (1500-4000cm-1) which may be similar for molecules within the 
same group (illustrated in Figure 1.21). Apart from the qualitative data obtained from an 
infra-red spectrum, concentration can be estimated using Beer Lambert law: 
A=ɛ│c 
Where: A=absorbance; ɛ=absorptivity; │= pathlength; c = concentration 
 
Figure 1.21 The fingerprint region and functional group region with examples of 
groups that may be involved in the regions136 
 
 1.6.3 The Infrared Spectrometer 
A Fourier Transform Infrared spectrometer contains an infrared light source, an 
interferometer, a detector, an optical system with a motorised x-y-z stage and a 
computer to process the data, as shown in Figure 1.22.  
 47
 Figure 1.22 The components in order of function of a FTIR Microspectrometer 
Traditional infrared spectrometers functioned by recording each part of the spectrum 
separately. The process started at one end of the frequency and swept to the other, and 
the detector signal was monitored and recorded. The process was slow and inefficient as 
apart from the frequencies where a transition occurred the majority of the time was 
spent recording background noise. A mathematical way of resolving complex waves 
(sinusoidal waves of different frequencies) into their frequency components was 
developed by Jean Baptiste Fourier in the early 1800s, however the technology to 
enable its application to spectroscopy was invented much later. The interferometer is the 
key component that has facilitated Fourier Transform Infrared Spectroscopy. The 
interferometer was invented by Michelson in 1880 and he was the first American to win 
a Nobel Prize in 1907 ‘for his optical precision instruments and the spectroscopic and 
metrological investigations carried out with their aid’. When a parallel beam of 
radiation is directed from a source to an interferometer the following happens: A beam 
splitter (a plate of transparent material coated in a suitable substance to reflect 50% of 
the radiation falling on it) splits the beam into two separate light paths. Half the 
radiation goes to a moving mirror and half to a fixed mirror (as illustrated in figure 
1.23). The radiation reflected from these mirrors comes back along the same path and is 
recombined to a single beam at the beam splitter (half the total radiation will be sent 
back to source). 
If monochromatic radiation is emitted by the source, the recombined beam leaving the 
beamsplitter towards the sample will show constructive or destructive interference 
depending on the relative pathlengths between the beamsplitter and the two mirrors. 
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Essentially if the pathlengths are identical or differ by an integral number of 
wavelengths, constructive interference will give a bright beam. If the difference is a half 
of an integral number of wavelengths the beams will cancel each other. The moving 
mirror governs the variation in pathlengths, and as it moves the intensity of the radiation 
leaving the beamsplitter to the detector will alternate. This is called an interference 
pattern – a perception of light intensity plotted against optical path difference. If the 
source emitted two monochromatic frequencies, two different interference patterns 
would be created and overlay each other. Although the detector would see a more 
complex pattern, computing the Fourier transform of the resultant signal would obtain 
the original frequencies and intensities emitted by the source. Taking the process 
further, the infrared light source in a FTIR spectrometer produces two broad band 
beams emitting all frequencies within its range, thus producing interference patterns that 
can be transformed back to the original distribution of frequencies. If the recombined 
beam is directed through a sample, the sample absorption will show up as a gap in the 
frequency distribution. Fourier transform analysis will convert this to a normal 
absorption spectrum. In practice the mirror is moved smoothly over a period of time 
through about 1 cm and the detector signal may be monitored every thousandth of a 
second into 1000 storage points. The computer then performs Fourier transform analysis 
on the stored data.  
Beamsplitter
Moving mirror 
IR source 
Sample 
Detector 
   Fixed mirror
Figure 1.23 A schematic of the interferometer in a Fourier transform spectrometer 
FTIR spectroscopy has several advantages over traditional infrared spectroscopy: 
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• Speed: it is not necessary to scan each wavenumber individually because the 
whole spectrum is contained in the interferogram which is measured in a few 
seconds 
• Resolution: Conventional instruments used a slit to focus the radiation but 
although a fine slit gives good resolving power it only allows a narrow spread of 
frequencies to fall on the detector at any moment so limited energy could be 
passed through the instrument and high gain was required resulting in significant 
noise. In FTIR because parallel beams are used no slit is required and all the 
energy passes through the instrument. The resolving power remains constant and 
is limited largely by the moving mirror and the computer capacity 
• The digital data obtained by FTIR is easier to analyse 
1.6.4 Additional Technical Considerations for Infrared Spectrometry 
Infrared microscopes are generally designed with two paths from the sample to the 
detectors: transmission and reflection. In transmission mode, the light passes through 
the sample and is collected on the other side. In reflection mode, the infrared light 
reflects off the sample and passes back through the illuminating objective. In reflection 
mode, approximately 40-50% of the incident light is blocked by a mirror that collects 
the reflected light. Thus transmission mode is preferred over reflection because of the 
increased incident flux on the sample. Reflectance is suitable for thin samples, highly 
reflective samples, materials which cannot be cut and when an infrared transparent 
substrate is either not available or prohibited due to budget but all these can cause 
different spectroscopic issues. 
Sample preparation is key to collecting good spectra. Organic samples are generally 
prepared with thicknesses of 10-15 microns. Specimens are mounted on a 1-2mm thick 
infrared transparent material; common materials used are listed in table 1.5. Of note 
potassium bromide is water soluble and diamond is expensive. 
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Material Transmission Range (cm-1) 
Calcium Fluoride (CaF2) 4000-1100 
Barium Fluoride (BaF2) 4000-800 
Zinc Sulphide (ZnS) 4000-600 
Potassium Bromide (KBr) 4000-400 
Diamond 4000-50 
Table 1.5 Materials with an infrared transparent window 
CO2 and H2O although only present in air in small percentages exert a significant 
absorption effect over much of the infrared spectrum. This obscures valuable spectra at 
similar frequencies. To remove this effect and study the regions impaired by these 
absorbances, the CO2 and H2O spectra would have to be subtracted from the spectrum 
of any sample analyzed under comparable conditions. However since the percentage of 
water vapour in the atmosphere is highly variable a background spectrum would have to 
be performed for each sample. This affects the quality of the spectra and is time 
consuming. There are two ways of overcoming this problem:  
1. Evacuation of CO2 and H2O from the spectrometer - this may be done by 
flushing a constant current of dry Nitrogen or dry CO2 free air though the 
system. This is unlikely to be completely effective as the equipment has many 
points that are permeable and let the outside atmosphere in. 
2. The alternative is to use two beams. The source radiation is divided into two by 
mirrors. One beam is brought into focus at the sample space, the other follows 
an equivalent path and is referred to as the reference beam. A moving mirror 
alternatively reflects the reference beam or allows the sample beam through the 
spaces into the monochromator. The detector sees the sample beam and the 
reference beam alternately. Both beams have travelled the same distance through 
the atmosphere and therefore are both reduced in energy by the same amount 
due to absorption by CO2 and H2O. If a sample capable of absorbing energy 
from the beam from the monochromator is placed in the sample beam, the 
detector will receive a signal altering in intensity because the sample beam 
carries less energy than the reference beam. This can be amplified and a 
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calibrated attenuator can be driven into the reference beam until the signal is 
reduced to zero, essentially both beams are balanced again. The distance 
travelled by the attenuator is a direct measure of the amount of energy absorbed 
by the sample. 
Most spectrometers use some form of amplification to magnify the signal produced by 
the detector. Every recorded spectrum will have a background of random fluctuations 
caused by the equipment and additional electronic signals. These fluctuations are 
referred to as noise. For a spectral peak to distinguish itself from noise its intensity must 
be approximately three to four times that of the noise. This may be referred to as a 
signal to noise ratio but highlights that there will be a lower limit on the intensity of 
observable signals. Computer averaging techniques can improve the effective signal to 
noise ratio.   
1.6.5 Attenuated Total Reflection FTIR 
Attenuated total reflection (ATR) is especially useful for samples which do not let light 
through because either they are highly absorbing or they cannot be cut into thin enough 
sections. The technique uses an ATR objective containing an ATR crystal made of an 
infrared transparent material, for example diamond, fitted to the FTIR spectrometer. The 
ATR crystal is used to probe the sample and must be in contact with the sample to 
work. Light entering the ATR crystal is totally internally reflected and collected in 
reflectance mode. When light normally inside the crystal escapes to be absorbed by a 
sample there is a reflection loss (evanescent waves). A reflection loss spectra can be 
created and adjusted for the depth of penetration of the sample. Although the ATR 
technique requires little sample preparation it can be time consuming when used with 
biological tissues, because the objective must be cleaned between spectral 
measurements at different points, and the sample must be raised and lowered between 
sample data points, therefore automated mapping is prohibitive. 
1.6.6 Synchrotron FTIR 
Synchrotron FTIR (S-FTIR) enables the acquisition of highly resolved images of 
microscopic areas less than 10 microns in diameter. This has practical application in the 
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analysis of the contents of small cells. This is achieved because the beam of radiation 
used by the synchrotron is approximately a few hundred microns in diameter; this is 100 
to 1000 times brighter than that emitted from a conventional infrared light source. 
Conventional spectrometers encounter a signal to noise ratio limitation when apertures 
confine the beam to 20-30 microns. S-FTIR is able to approach beamlines of 3 microns 
in diameter with an acceptable signal to noise ratio thus enabling the detailed 
interrogation of cells. 
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1.7 Biomedical Applications of Fourier 
Transform Infrared Spectroscopy 
Vibrational spectroscopy techniques including Fourier Transform Infrared Spectroscopy 
have recently been applied to address biomedical problems. The concept is not new; in 
1949 and 1952 Blout, Mellors and Woernley reported that infrared spectra of human 
and animal tissues could provide information on the molecular structure of tissue137,138. 
Unfortunately, at that time the technology required to practically realise their visions 
was not available. The development of sensitive and high throughput spectrometers in 
the last decade has enabled simultaneous global analysis of biological samples and high 
resolution molecular information to be obtained.  Spectroscopic findings are dependent 
on tissue architecture, the light absorbing or scattering properties of each layer, and the 
biochemical microenvironment of the tissue. Spectroscopy is non-destructive, requires 
no extrinsic contrast enhancing agents and allows samples to be analysed directly at 
room temperature and pressure. This section describes the broad range of FTIR’s 
biomedical applications before a critical review of FTIR experimental studies performed 
on the prostate. Competing technologies will be discussed in Chapter 1.8. 
1.7.1 FTIR Spectrometry for Molecular Structural Analysis 
In complex biological cells and tissues the infra red spectrum is an expression of the 
sum of all the biomolecules present. The most significant components of most 
biological tissues and cells are proteins, carbohydrates and lipids. Analysis of the 
structural information obtained about these constituents by FTIR enables the 
differentiation and determination of clinically relevant factors. 
Proteins: proteins are macromolecules, they consist of series’ of amino acids known as 
polypeptides. The way in which these polypeptides are put together is termed the 
secondary structure. FTIR can be used to determine the secondary structure of 
proteins139. The structure can be determined in terms of percentages of α helix, parallel / 
anti parallel β sheets, β turn and unordered structure present in a sample140. 
Spectroscopists commonly use amide groups to determine the secondary structure of 
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proteins. Amide I (-CONH2-) is located at approximately 1700-1600 cm-1, Amide II (-
CONH-) is located at approximately 1550cm-1. The position in the frequency range 
where the amide bands appear is dependent on the hydrogen bonding of the C=O and N-
H groups141,142. Differentiation of pathologies on the basis of changes in protein 
concentration alone has been demonstrated to be limited by the fact that significant 
variations in cellular protein structure may occur, dependent on the position of the cell 
in its cycle rather than only due to the carcinogenesis process143,144. 
Carbohydrates: carbohydrates are an important source of energy in cells and fuel the 
majority of processes in the cell. Carbohydrates are most commonly found stored as 
glycogen in the cell, a polysaccharide chain. Glycogen is broken down into its 
constituent units of glucose to provide energy for cellular processes. Carbohydrates may 
also be found bound to lipids, proteins or the ribose moiety of nucleic acids. Key FTIR 
carbohydrate absorbencies arise at 1170cm-1, 1050cm-1, 1030 cm-1 145. The significance 
of changes in concentration of carbohydrates in the cell may give an indication of 
pathological processes occurring in the cell and this is discussed later in the chapter.  
 
Lipids: Lipids are also present in cells, and comprise fatty acid chains. Their 
absorbencies are largely due to their long hydrocarbon chain moieties (CH2 and CH3). 
The carboxylic acid moiety of fatty acids has a carbonyl stretch absorbance at 
approximately 1725 cm-1 and the carbonyl group of phospholipids characteristically 
absorbs at 1740 cm-1. The phosphate component of phospholipids prevalent in cell 
membranes has absorbance peaks at 1080 cm-1 and 1240 cm-1 for symmetrical and 
asymmetrical modes of PO2 respectively146. Changes in lipid concentration may signify 
changes taking place in the membranes of the cell.   
 
1.7.2 The Cell Cycle 
 
The cell cycle is the process by which normal cells proliferate, essentially mitosis (cell 
division), and is illustrated in Figure 1.24. The cycle starts with G1, a gap phase, this is 
the time between previous mitotic division and the next phase beginning. During the S 
phase DNA synthesis occurs, leading to the cell DNA content to be doubled. Once 
synthesis is complete there is a second gap phase, G2, before cell division occurs. In the 
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M phase mitosis occurs in two stages: firstly the DNA separates and then cytokinesis 
occurs. After this phase cells enter the G0 phase, this is a period of growth arrest until 
cells are stimulated to resume the cell cycle147.  
 
G2 G1 
S
M
G0
Figure 1.24 The cell cycle 
 
Several mechanisms exist to control the cell cycle. Proteins which regulate the cell cycle 
include growth factors, cyclin dependent kinases and cyclins. Apoptosis (programmed 
cell death), is another important mechanism by which abnormal cells or cells which are 
not needed are eliminated thus regulating proliferation. In malignancy, the normal 
mechanisms of control of cell proliferation do not operate. One theory for proliferation 
in malignant prostate cells is that p53 and Bcl-2, proteins which control apoptosis, are 
over expressed leading to apoptotic resistance148. Differences in cell biochemistry 
resulting from alterations in the normal cell cycle may be identified by FTIR. 
 
1.7.3 Biochemical Changes During Carcinogenesis 
 
The proliferation of an invasive cancer cell capable of local and distant spread is 
dependent on oxygen delivery and glucose metabolism. Metastatic tumour cells have a 
high glycolytic metabolic profile and are likely to have low intercellular oxygen 
tensions (pO2) as a consequence of high respiration rates (both anaerobic and 
aerobic)149. An increase in glycolytic rate results in decreased cellular concentrations of 
glycogen, especially in tumour cells. Neoplastic cells must be within a 1-2mm3 
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proximity to a blood supply to survive otherwise they will become hypoxic and 
eventually necrotic150. A viable blood supply enables the transport of nutrients to 
proliferating cells but also enables the waste products of carcinogenesis to be removed. 
Tumours with the capability to induce formation of new vessels are particularly 
pathogenic; vascular endothelial growth factor (VEGF) is an example of a potent 
angiogenic factor151. Tumour cells with a poor micro-circulation become hypoxic. Low 
oxygen tension combined with a poor oxygen supply and removal mechanism leads to 
increased anaerobic respiration and a several fold lactic acid production152. It is 
acknowledged that even in aerobic respiration tumour cells produce large amounts of 
lactic acid; this is termed the Warburg effect152. The removal of lactic acid is also 
impaired by the poor circulation. Acidic intracellular and extracellular pH is therefore 
associated with tumour progression and also ischaemia. 
 
In the process of necrosis special enzymes are released by lysosomes, which are capable 
of digesting cell components or the entire cell. This tissue destruction also results in 
lactate production. 
 
Carcinogenesis is associated with increased free radical generation. This is 
acknowledged to induce the formation of lipid, protein and DNA peroxidation 
products153. Phosphocholine and Glycophosphocholine are important metabolites of 
phospholipid metabolism and are noted to be present in increased quantities in actively 
dividing or cancerous cells154. 
 
The critical review which follows describes the way that some of these factors have 
been used to form a basis of objective discrimination of pathologies. 
 
1.7.4 FTIR and Clinical Chemistry 
 
FTIR has been able to determine molecular concentrations of glucose and cholesterol in 
blood155, and protein, creatinine and urea present in urine156 with good accuracy 
compared to clinical gold standards. The practical application of this has been limited to 
date because frequently spectra from different molecules have overlapped in complex 
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biological molecules especially at protein absorptions. Proteins are major constituents of 
these fluids, and their spectra may mask the spectral information from other sample 
contents157. These limitations can be overcome by either modifying data processing 
methods or by using specific transparent windows which are wavelengths where 
minimal overlapping and known key absorptions occur. 
 
1.7.5 FTIR and Microbiology 
 
Fourier transform infrared spectroscopy is used to classify microorganisms in many 
non-medically related fields currently, including bioprocess and fermentation 
monitoring158. Organism identification using FTIR analysis is achieved by utilising 
pattern recognition algorithms such as cluster analysis or linear discriminant analysis 
(LDA). The principles have been applied to enable classification of common pathogens 
for example Enterococcus species, an organism found in the gut and a leading cause of 
noscomial infections. A comparative study combined the use of phenotypic, genotypic 
and vibrational spectroscopy techniques to type a collection of Enterococcus strains. 
Classification by FTIR identified discrepancies in strains classified using the phenotypic 
systems. The discrepancies were resolved by using elaborate polymerase chain reaction 
(PCR) and genotypic methods to reclassify the strains in question. The correct strains 
were consistent with FTIR findings159. Thus FTIR has demonstrated promise as a 
microbiological classification tool. 
 
1.7.6 FTIR and Pathology 
 
The potential of FTIR for rapid, high resolution, unstained biochemical tissue analysis 
is being investigated. Ultimately it is hoped that the technology will not only reliably 
distinguish between pathologies but also enable identification of premalignant 
pathologies and prediction of clinical outcome. FTIR has been applied/studied in the 
following malignancies: colon160, cervix161,162, stomach163, breast164, skin165, oral166, 
pancreas167, lung168 and cerebral169. To date although FTIR has been applied to a 
number of biological tissues to distinguish pathology, universal patterns for 
distinguishing between benign and cancerous tissues have proved elusive. Studies have 
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been limited by small sample numbers and their lack of clinical application; maybe due 
to the lack of partnership between spectroscopists and clinicians in study design. The 
next part of the chapter will review the literature specifically regarding FTIR and the 
prostate to illustrate the applications of FTIR to pathology. 
 
1.7.7 FTIR of the Prostate 
Fourier transform infrared spectroscopy has been applied to urological pathologies over 
the last decade. Exciting work has been reported in prostate tissue, cell and DNA 
studies. 
 
Tissue studies 
Pilot studies evaluating the ability of FTIR to distinguish between benign and malignant 
prostate pathology to date have used small highly selected numbers of spectra from a 
small number of prostate tissue samples to test the hypothesis. Gazi et al170, concluded 
that FTIR could discriminate between benign and malignant prostate pathology using an 
average of four spectra from each pathology, from five deparaffinated prostate tissue 
samples, each mounted on KBr and obtained at transurethral resection of the prostate 
(two BPH, three CaP). The FTIR spectra from single Gleason grades were examined, 
however no clear relationship was determined. A difference in pathology 
glycogen/phosphate ratio was proposed to explain the differentiation. Malignant cells 
have a high metabolic turnover and therefore a lower glycogen content. Thus benign 
samples had a glycogen/phosphate ratio of greater than or equal to 0.6, and malignant 
samples a ratio below 0.4. Similar findings have been reported in colorectal studies and 
pure biochemical studies of the prostate171,172. The potential negative effect of diathermy 
used at TURP on the biochemistry of tissue and thus biochemical analysis obtained at 
TURP was not addressed. Paluszkiewicz et al. used FTIR to analyse fresh frozen 
prostate tissue mounted on mylar foil173. Although the origin and number of samples 
was not defined, and the mylar foil may have affected the FTIR spectra,  it was 
concluded that cancerous tissue could be distinguished from non cancerous by FTIR 
using the vasCH2/vasCH3 peak ratios at 2930 cm-1 and 2960 cm-1 respectively, and 
the/vsCH3 peak ratios observed between 2852 - 2874 cm-1. Without knowledge of the 
origin and number of the tissue samples upon which this study was based in addition to 
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factoring in the variance of the mylar foil effect and the fact that the ratios proposed are 
outside the ‘fingerprint region’, further validatory studies are required to confirm these 
findings. 
 
More recently the same group has addressed some of the aforementioned issues. 
Synchrotron FTIR and FTIR Spectroscopy was used to evaluate five prostate samples 
mounted on mylar foil taken from five samples at prostatectomy174. Two 
prostatectomies were performed for benign disease, two were performed to remove 
prostate cancer and one prostate was removed during a cysto-prostatectomy for bladder 
cancer. This study concentrated on examining the spectral characteristics of prostate 
tissue between 3700 cm-1 and 2800 cm-1, particularly where the C-H stretching 
vibrations are located. They concluded that by using the CH2/CH3 ratio it was possible 
to differentiate between normal, benign prostatic hyperplasia and cancerous tissue using 
both FTIR and S-FTIR. Similar findings have been reported in FTIR analysis of breast 
cancer tissue and prostate cells175,176.   
 
Attempts have been made to correlate the FTIR spectra taken from cancerous prostate 
tissue with Gleason score and clinical stage of prostate cancer at the time of biopsy177. 
The heterogeneity of the tissue studied unfortunately may have affected / limited the 
interesting study findings. Of 40 cancer samples, all were originally paraffinated, and 
37/40 were TURP specimens. Fifty-nine percent of the samples came from patients who 
were undergoing hormone manipulation for their prostate cancer. In addition to this 
relatively few highly selected spectra from four samples were used to create the test 
model. A total of 383 spectra were collected. FTIR was able to predict precise Gleason 
grade with an accuracy of 20 % if two grades were present in the tissue, and 17% if only 
a single grade was present in the tissue. If the criteria were adapted to those used by 
Crow et al178 in Raman spectroscopy to determine the Gleason score of prostate cancer 
(<7, 7, >7), the sensitivities and specificities rose to greater than 70%. A poor 
correlation was found when it was attempted to determine disease stage from FTIR 
spectra. Gleason grade had a sensitivity and specificity of 71% and 67% respectively in 
determining disease stage. Further work by Baker et al has developed the technique 
further using supervised principal component discriminant function analysis. The 
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sensitivities and specificities of discrimination for Gleason <7,7,>7achieved are much 
improved 92.3% and 98.9% respectively and the potential of FTIR to stage disease have 
been explored179. This early work is promising but uses under 400 spectra from two 
separate paraffinated tissue sources (TURP and biopsy tissue from - a highly selected 
group) to build its diagnostic algorithm which may compromise its wider application.  
 
German et al used FTIR with an ATR crystal and synchrotron FTIR to investigate 
whether FTIR would be able to differentiate structural characteristics between different 
prostate zones180. Paraffinated samples were obtained from six patients who had 
undergone radical retro-pubic prostatectomy and analysed. In benign prostate tissue five 
spectra were taken at three individual points at each of three randomly chosen glandular 
elements. In cancerous tissue three spectra were taken at five randomly chosen 
glandular elements. Five randomly chosen measurements were taken from the adjacent 
stroma of both benign and cancerous tissue.  In contrast to Gazi’s findings, no tissue or 
region specific characteristics were determined, especially between 1000-1200 cm-1 in 
either epithelial or stromal cell regions. The authors comment on the presence of a 
prominent paraffin wax peak at 1462 cm-1. When principal component analysis was 
applied to the dataset, subtle differences between PZ, TZ and CaP regions were 
determined, especially in the region containing the DNA/RNA bands 1000-1490 cm-1 
using ATR spectroscopy, and between 1000-1200 cm-1 region in synchrotron FTIR 
analysis. Good separation was demonstrated between CaP free tissues (PZ, TZ) and 
CaP. The group also performed an interesting study of the PZ and TZ taken from a 
cancer free prostate gland taken at cysto-prostatectomy which was immediately snap 
frozen. The spectra were compared with spectra from deparaffinated prostate tissue. 
Although PZ spectra were tightly grouped there was variation between the TZ spectra. 
Differences were noted in both the PZ and TZ spectra between the 1700-1750 cm-1 
region, associated with the C=O stretching vibrations of lipids (1740 cm-1) with a peak 
not seen in deparaffinated sections. In the spectral region 1490-1000 cm-1, containing 
the DNA/RNA, median intensity elevations were determined in PZ tissue of 
glycoproteins (1380 cm-1), amide III (1260 cm-1), and carbohydrates (1155 cm-1) when 
compared to the TZ. This may point to differences between epithelial cells in this region 
or it may be a factor of the sample being affected by the processing as the prostate is a 
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large gland, to snap freeze the inner core will freeze at a different time to the periphery. 
Biopsy comparison may in the future remove this issue. 
 
Cell studies   
Fixatives are used in histopathology to preserve the structural and biochemical 
constituents of cells as close to in vivo conditions as possible. Without fixation, cells 
would initially alter in size, shape and consistency and eventually decompose by 
autolysis making morphological analysis impossible. For the same reason, biochemical 
analysis of a cell would not be representative of in vivo conditions if fixation was not 
used. However, the biochemistry of samples is also disrupted by cross-linking fixatives. 
FTIR studies to date have addressed this issue by studying fresh frozen tissue, but 
practically, FTIR analysis of fixed tissue is mandatory if this technology is going to be 
clinically useful and validated in the near future. 
 
Synchrotron FTIR has been used to evaluate some of the changes which take place 
within cells during the fixative process. Routinely used histopathological stains were 
used as a standard against which to compare the changes occurring. The prostate cancer 
cell line PC-3 was used for these studies. Tryptan blue was used to assess the effect of 
fixatives on membrane integrity morphologically. Cells with no fixative, formalin fixed, 
unfixed formalin and gluteraldehyde were assessed. Tryptan blue illustrated that only 
gluteraldehyde maintains membrane integrity when used in fixation. Synchrotron FTIR 
analysis was able to determine the cytoplasm and nucleus in formalin and 
gluteraldehyde fixed cells. S-FTIR was unable to differentiate the cell components 
clearly in unfixed cells181. Harvey et al recently determined that growth media and 
nuclear to cytoplasmic ratio are unlikely to explain FTIR’s differentiation of pathology; 
it is likely to be due to biochemical differences182.  
 
DNA Studies 
Malins et al have used FTIR to study DNA sourced from frozen benign and malignant 
prostate tissue. FTIR achieved sensitivities and specificities of greater than 95% when 
differentiating DNA extracted from normal tissue, BPH and prostate cancer in 29 
samples. No relationship between FTIR analysis and Gleason grade was established183. 
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DNA studies have demonstrated that it is also possible to differentiate between non 
metastatic prostate cancer DNA and metastatic prostate cancer DNA184. FTIR analysis 
of age related changes in prostate DNA, DNA in adjacent tissue areas and markers of 
susceptibility for prostate cancer have not yielded convincing results185,186.   
 
Tissue Microarray Studies 
FTIR spectroscopy has recently been combined with tissue microarray technology187. 
FTIR analysis of microarrays constructed from formalin fixed archival samples from 
sixteen patients representing the main prostate pathologies, achieved classification 
accuracies of greater than 95%. The reported ability of the technique to differentiate 
between nerves, blood vessels and lymphocytes is both novel and exciting. The origin 
and Gleason grade of the tissue used to create the microarrays was not discussed in the 
paper and is a potential weakness of the study, however the potential advantages of 
microarrays in FTIR laboratory studies are clear: 
• Microarray size and purity enable rapid acquisition of high quality FTIR data 
• Microarrays could facilitate large scale validation studies of FTIR analysis 
FTIR microarray studies may therefore accelerate the development of FTIR diagnostic 
algorithms which could be investigated in the clinical arena. 
 
1.7.8 Limitations of Prostate FTIR Studies To Date 
 
The studies discussed in this chapter illustrate the potential application of FTIR as a 
pathological classification tool. To date the majority of FTIR studies of the prostate 
include a small number of patient samples and varied methodology in tissue processing 
and analysis. Whilst a technique is being established, power calculations are less 
important than developing rigorous, repeatable methodology that may be used in large 
scale trials.  It is also important that the application is tested in the target population in 
which the technology is likely to be used. Complex computer programs are used to 
determine the spectral differences between pathologies, and cross-validation of the 
discriminating regions reported is also essential for the FTIR to be accepted in practice. 
Some of the proposed regions will be evaluated in the studies which follow. The 
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majority of studies have also failed to present FTIR analysis of control samples from the 
same patients in their results.  
 
The primary clinical aim for pursuing FTIR technology as a clinical tool is to enable 
rapid diagnosis of pathology in prepared or unprepared tissue. Whilst important small 
steps have been taken in understanding the technology and its versatility in prostate 
tissue analysis, there is still a need to validate the technique for its potential future 
clinical purpose before large scale studies can be commenced. These issues will be 
addressed in the experiments in this thesis. Ultimately it is hoped that FTIR may have 
the potential to identify the presence of cancer even if a morphologically normal sample 
is being interrogated, and aid early diagnosis of biologically significant prostate cancer. 
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1.8 Competing Technologies 
 
1.8.1 Raman Spectroscopy 
 
Raman spectroscopy is another form of vibrational spectroscopy which is 
complementary to infrared spectroscopy. Instead of analysing light passing through a 
sample, it collects and analyses how samples scatter light. Raman spectroscopy utilises 
monochromatic light from the ultra violet, visible or near infrared part of the 
electromagnetic spectrum. The optimum excitation wavelength for analysing human 
epithelial tissues has been found to be 830nm in the near infra red region of the 
spectrum188. The principle is that when a tissue is illuminated with monochromatic laser 
light, approximately one in a million of the light photons will inelastically interact with 
an intramolecular bond in a tissue. The interaction will result in energy being donated or 
received from the bond. This changes the vibrational state of both the bond and the 
photon. The resultant photon will have a different energy to the incident photon. This 
energy change is known as a Raman shift and is specific to each species of 
intermolecular bond. A Raman spectrometer collects all the photons with shifted 
wavelengths to produce a spectrum. The Raman spectrum is a plot of light scattering 
intensity against Raman shift. In the same way as FTIR, a Raman spectrum is a direct 
function of the molecular composition of the sample in question and therefore an 
objective measure of the pathology present. 
 
Molecular vibrations may be either infrared or Raman active or both, therefore the 
techniques may be used together to gain a greater understanding of a samples molecular 
structure. Key technical differences between the techniques are highlighted in table 1.6. 
 
Raman spectroscopy has demonstrated considerable potential in the identification of 
epithelial cancers189. In the urological field, Crow et al have demonstrated that Raman 
spectroscopy is capable of accurately identifying and grading bladder cancer and 
prostate cancer in vitro190. The potential of Raman spectroscopy for in vivo application 
has also been demonstrated by utilising a fibre-optic probe in vitro to distinguish 
between prostate and bladder malignancies191. A modification to the Raman 
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spectrometer called Kerr-gating has also demonstrated significant promise in increasing 
the sensitivity of Raman signal in the analysis of dark urological tissues192. The Kerr 
gate is a high speed shutter that limits the majority of fluorescence which can 
significantly affect the Raman signal collected in routine analysis. Kerr gating has 
allowed early work into depth profiling of prostate and bladder tissue with potential 
application in targeting prostate biopsies. 
 
Currently in urological tissue analysis, high quality infrared spectra are quicker to 
obtain than Raman spectra in vitro, developments in technology have allowed FTIR 
spectral imaging of samples to be performed, the benefit of this will be explored in this 
thesis. Raman has great potential as a probe, in vivo, application due to its spectra not 
being affected significantly by water and will no doubt be complementary as an optical 
technique ex vivo to FTIR. 
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Raman Spectroscopy Mid-Infrared spectroscopy 
Uses higher energy light photons in the 
form of a laser and measures the 
difference between ground state and first 
vibrational state by subtracting the energy 
of the inelastically scattered photon from 
the incident photon 
Uses low energy infrared light photons to 
result in a direct excitation of a molecule 
to its first vibrational state. The energy of 
the photon achieving this is identical to 
the energy difference between ground 
state and first vibrational state 
Results from a change in the 
polarizability of the electron cloud 
around the molecule 
Results from absorptions caused by 
change in dipole moment 
The Raman spectrometer displays the 
result of Raman scattering as a spectrum. 
The shift in energy from that of the laser 
beam is calculated by subtracting the 
scattered energy from the incident 
energy. The scattered light is collected by 
the spectrometer and the y axis represents 
scattered light detected versus 
wavenumber on the x axis. The 
maximum light detected is at the top of 
the trace 
In Infrared absorption spectra the y axis 
is the amount of light absorbed and the x 
axis wavenumber. The peaks represent 
the light energy absorbed by the 
molecule. Maximum absorbance is at the 
highest point of the trace. In 
transmittance maximum absorbance is at 
the lowest point of the trace. 
Region of interest 3600-200 cm-1 Region of interest 4000-400cm-1 
Water does not significantly interfere in 
near infrared Raman 
Water interferes in infrared spectroscopy 
as it is absorbed in the mid ir wavelengths
Hydroxyl and amine stretch groups in 
addition to carbonyl groups are weakly 
determined in Raman. However the C=C 
bond is strongly determined in Raman. 
Hydroxyl and amine stretch groups in 
addition to carbonyl groups are strong in 
infrared spectroscopy. The C=C bond 
does not feature in an infrared spectrum. 
   
Table 1.6 Contrasting features of infrared and Raman spectroscopy 
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1.8.2 Magnetic Resonance Spectroscopy 
 
Magnetic resonance spectroscopy (MR spectroscopy) is a technique which is able to 
determine the concentrations of organic compounds in vivo. MR spectroscopy is a 
theoretically complex tool based on the quantum mechanics of magnetic properties of 
an atom’s nucleus. Most of the atoms within samples placed within a magnetic field will 
spin along the axis of the field. The energy states of these atoms can be altered by 
changing the magnetic field from low energy spinning to high energy spinning. MR 
spectroscopy measures the energy difference between these states and produces a 
spectrum. Each individual atom will have its own characteristic spin. 
 
The technique is acknowledged to have the potential to provide diagnostic and 
prognostic information. The MR fingerprint from samples of the cervix193, brain194, 
thyroid195, colon196, ovary197, breast198, oesophagus199 and liver200 have detected and 
differentiated between disease with sensitivities and specificities of greater than 95%. 
Magnetic resonance spectroscopy has also been piloted to assess prognosis in human 
cancers201, 202. 
 
The technique has been applied to the prostate with success in differentiating benign 
and malignant pathologies. Choline, creatinine, citrate, myo-inositol, lipid, spermine 
and lysine have all been found to be useful in distinguishing the various patterns of 
prostatic disease203,204,205,206,207,208,209,210. MR spectroscopy has also demonstrated the 
capacity to be able to profile tumour location. Work is now being pursued to 
reproducibly characterize prostate cancer. 
 
The technique has demonstrated limitations in classifying central and transitional zone 
tumours but is likely to be a promising adjunct in the preoperative staging of prostate 
cancer. It is unlikely to be in direct competition with infrared spectroscopy as a 
diagnostic pathology tool. 
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1.8.3 Optical Coherence Tomography 
 
Optical coherence tomography (OCT) obtains high resolution cross-sectional imaging 
of human tissue. OCT works in a similar way to ultrasound; when light from a pulsed 
laser or superluminescent diode is directed at a tissue, it is reflected or backscattered by 
structures within the tissue. OCT uses the estimates from the time taken for light to 
return from the structures to produce detailed images. OCT has demonstrated promise in 
differentiating the architectural morphology of urological tissue211. This technology is 
being pursued to enhance surgical precision during prostate surgery. Although early 
work in vivo has demonstrated a reasonable correlation between urological surgical 
perceptions and OCT images of prostate tissue, further parallel histological studies are 
required to validate the findings of OCT imaging212.  
 
1.8.4 Recent Spectroscopic Technologies Applied to the Prostate 
 
Fluorescence spectroscopy evaluates the energy emitted by a molecule as it returns to its 
ground state after it has been excited by a light energy source. Emission radiation is also 
known as fluorescence and the emission wavelengths generally mirror the absorption 
spectrums. The fluorescence of a molecule is dependent on the number of emitted 
photons compared to the number absorbed and the time taken to return to ground state. 
Fluorescence may be dependent on natural endogenous properties or rely on exogenous 
chemicals to induce fluorescence. High frequency impedance spectroscopy uses the 
dielectric properties of a medium and its interaction with an external electric field to 
produce a spectrum. The result of a feasibility study of these novel technologies has 
recently been published, reporting differentiation of benign and malignant pathology 
with high sensitivity and specificity213.    
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1.9 Aims and Objectives 
 
A review has been presented demonstrating the clinical significance of prostate cancer 
and the urgent need for more sophisticated objective diagnostic and prognostic 
techniques. The concept of spectroscopic technologies potentially filling this role has 
been introduced and the limitations of previous FTIR prostate studies discussed. The 
body of the thesis which follows investigates the potential application of Fourier 
Transform Infrared spectroscopy (mid-IR) as a tissue diagnostic technique to 
complement histopathology by giving additional information and its potential for 
automation. The studies which follow are clinically based in principle encompassing the 
fundamental requirements of clinicians in any prostate gland investigation. 
 
The hypothesis being tested in the studies was that FTIR has the ability to distinguish 
objectively between prostate pathologies. 
 
The objectives of this study can be classified into two parts: 
 
Part One  
• Observe whether FTIR analysis can be correlated to histopathological analysis 
of benign, malignant and premalignant tissue in prostate studies. 
• Observe whether the ability of FTIR to classify pathologies is affected or 
changed by type of prostate tissue sample studied. Tissue from radical 
prostatectomy, trans-urethral resection of the prostate and prostate core biopsies 
(all possible clinically relevant samples) have been included in this study. 
• Observe the effects of fixation on FTIR analysis contrasted with analysis after 
the fixative has been removed, using the same sample to ensure an appropriate 
control. 
• Observe the contrast between FTIR analysis of tissue which has been fixed 
against fresh frozen tissue. 
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 Part Two 
• If there are significant biochemical differences between prostate pathologies, 
evaluate whether they are transferable between tissue samples 
• To apply parametric non negative least squares analysis to the spectra obtained 
to attempt to gain further understanding of these differences and the 
carcinogenesis process 
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“ I think your solution is just; but why think? Why not try the experiment? ”  
John Hunter 1728-1793 
 
2. Materials and Methods 
 
Gloucestershire Local Research Ethics Committee granted ethical approval to collect 
prostate tissue from appropriately consented patients for FTIR spectroscopic studies 
(Gloucestershire Local Research Ethics Committee no. 00/159G). This section describes 
how samples were collected and prepared for analysis. The samples were analysed 
using a laboratory based bench-top Fourier Transform Infrared Microspectrometer at 
Gloucestershire Royal Hospital; the spectrometer and analysis methods will also be 
described. 
 
2.1 Prostate Tissue Collection and Preparation 
2.1.1 Transurethral Resection of the Prostate Specimens: Collection 
Transurethral resection of the prostate (TURP) samples were collected at routine 
operating lists at Gloucestershire Royal Hospital. All patients were undergoing surgery 
for bladder outflow obstruction and had consented to have one of their TURP chips 
used for research purposes. The samples were taken using a resectoscope (Stortz 27040 
DH). Figure 2.1 illustrates transurethral resection of a prostate chip. Figure 2.2 shows 
how multiple chips are obtained during this procedure. None of the patients were known 
to have prostate cancer prior to their procedure. Each prostate chip was positioned on a 
section of acetate paper which had been marked on one corner to enable orientation of 
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the sample. The acetate together with the sample was then placed in a 2ml cryogenic 
vial (Corning Incorporated). The vial was immediately placed into liquid nitrogen to 
snap freeze the sample. The sample was stored in a -80°C freezer between collection 
and sectioning. Each frozen sample was sectioned using a cold cryotome at 
approximately -28°C. Sections were 8-10μm in thickness. Consecutive sections were 
mounted onto a histology slide (Snowcoat X-tra, Surgipath) for standard haematoxylin 
and eosin staining and a calcium fluoride slide (Cystran Limited) for later FTIR 
analysis. The remainder of the sample was replaced in the cryogenic vial and returned to 
the -80°C freezer together with the mounted calcium fluoride slide pending FTIR 
examination. In total fifty TURP chips were collected, of which 27 TURP samples were 
used for the FTIR mapping studies. A relatively small number of prostate specimens 
were included in the final analysis due to difficulties obtaining suitable samples for 
FTIR analysis using the cryotome. Table 2.1 illustrates how the samples were broken 
down. 
 
 Benign 
 
Malignant 
Pathology 
 
BPH and stroma Adenocarcinoma prostate 
Number of 
Samples 
23 4 
 
Table 2.1 The pathology of the TURP samples included in study 
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 C = Prostate chip 
R = Resecting loop 
P = Residual prostate 
R 
C 
P 
Figure 2.1 Resection of a prostate chip using electrode 
 
 
Figure 2.2 Example of total prostate tissue removed as multiple chips during 
TURP 
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2.1.2 Transrectal Ultrasound Guided Prostate Biopsy specimens: Collection 
Prostate biopsy samples were collected from patients at Gloucestershire Royal Hospital 
and Cheltenham General Hospital. Patients attending for biopsy had been previously 
reviewed by a urologist and were suspected to have prostate cancer on the basis of 
either an elevated PSA blood test or abnormal digital rectal examination or both. All 
patients gave consent for an extra biopsy to be taken and used for purely research 
purposes. The biopsy was positioned onto a section of acetate paper, which had been 
marked on one corner, placed in a cryogenic vial and snap frozen in liquid nitrogen. The 
sample was stored in a -80°C freezer between collection and sectioning.  The specimen 
was sectioned as described above in section (2.1.1). Of fifty biopsy samples obtained, 
33 were suitable for final FTIR analysis after sectioning. Figure 2.3 illustrates a biopsy 
section prior to FTIR analysis. Table 2.2 details the breakdown of pathology in the 33 
biopsies included in FTIR studies. Table 2.3 details the most recent PSA reported prior 
to TRUS biopsy (where recorded), the final formal TRUS biopsy histology and the 
research biopsy histology in each sample. 
Pathology No evidence of 
malignancy 
Adenocarcinoma 
of the prostate 
Prostatic 
Intraepithelial 
Neoplasia 
Number of 
samples 
28 4 1 
Table 2.2 The pathology of prostate biopsy sections included in study 
 
 
 
Figure 2.3 White light image of a prostate biopsy section prior to FTIR analysis 
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Sample No PSA TRUS pathology Research biopsy 
 
1 4.2 3+3=6, single left 
core 
NM 
2 8.5 3+3=6, multiple 
cores left and right 
NM 
4 8.5 NM NM 
5 9.0 3+4=7, multiple left 
cores 
NM 
6 288 5+3=8, multiple 
cores left and right 
Malignancy 
7 3.6 NM NM 
8  NM (2nd set Bx) NM 
10 7.8 4+5=9, multiple right 
cores 
NM 
11 170 5+4=9, multiple 
cores left and right 
Malignancy 
12 8.1 PIN NM 
13 13 3+2=5, multiple 
cores left and right 
NM 
14 6.8 NM NM 
15 30 4+3=7, multiple 
cores left and right 
NM 
18 5.4 NM NM 
19 15 NM NM 
20 7.9 NM NM 
21  NM NM 
22  NM NM 
23  NM NM 
25 17 NM NM 
26 14 3+3=6, multiple right 
cores 
NM 
27 12 NM NM 
28  NM NM 
29 139 4+4=8, multiple 
cores left and right 
Malignancy 
30  3+3=6, multiple 
cores left and right 
NM 
31 8 NM NM 
32 11 3+4=7, multiple 
cores left and right 
Malignancy 
33 6.7 NM NM 
34 93 3+4=7, multiple 
cores left and right 
NM 
36  4+4=8, multiple 
cores left and right 
NM 
38 4.1 NM NM 
39 27 3+4=7, multiple left 
cores 
PIN 
42 6.2 NM NM 
Table 2.3 The characteristics of the TRUS Biopsy specimens included in study 
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2.1.3 Radical Prostatectomy Specimens: Collection 
Patients undergoing radical prostatectomy for treatment of their prostate cancer at 
Gloucestershire Royal Hospital were consented for FTIR analysis of sections of their 
prostate after histological analysis of their prostates for formal post operative 
pathological staging had been completed. These samples differed from the tissue 
samples taken above because instead of snap freezing the prostate tissue, the prostate 
tissue was formalin fixed and paraffin embedded post operatively prior to histological 
and FTIR analysis. The analysis of this tissue forms a key part of this thesis because this 
represents how prostate tissue is routinely fixed and analysed in current clinical practice 
and the heterogeneity within each sample provides an intrinsic control for each 
specimen. A description of how the radical prostatectomy specimen was fixed follows 
below in section 2.2.3. Consecutive ten micron transverse prostate sections were taken 
from selected paraffin embedded blocks using a microtome, and mounted on glass and 
calcium fluoride slides for histological and FTIR analysis respectively. Sections were 
analysed by FTIR in both paraffinated and deparaffinated states. Table 2.4 details the 
pathology groups within each sample. 
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Radical prostatectomy specimen Pathologies within specimen 
1 BPH, Prostatitis, Prostatic Calculi, PIN, 
Gleason 4+3=7 
2 BPH, Gleason 3+4=7 
3 No BPH, Gleason 3+3=6 
4 PIN, Gleason 4+3=7 
5 BPH, Gleason 3+4=7 
6 No BPH, Gleason 3+4=7 
7 No BPH, PIN, Gleason 3+3=6 
8 No BPH, PIN, Gleason 3+3=6 
9 BPH, PIN, Gleason 3+4=7 
 
Table 2.4 Pathology of the radical prostatectomy specimens included in the study 
 
2.1.4 TURP, Prostate biopsy and Radical Prostatectomy Specimens: Histological 
Examination 
 
The stained haematoxylin and eosin (H & E) sections were examined by a consultant 
uropathologist at Gloucestershire Royal Hospital, Dr Jeremy Uff. The mark placed on 
the specimen prior to initial snap freezing allowed sample orientation and relative 
mapping of locations of prostate pathology present. The pathologist defined and 
recorded the prostate pathologies present within the sample with the principal researcher 
present. If prostate cancer was identified within a specimen, a Gleason grade was 
assigned and the sample was re-examined by a second consultant pathologist with a 
special urological interest and concordance in Gleason grade agreed. The areas of 
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interest were marked on the H & E slides in indelible ink, relative positions of the 
pathologies were measured and allocated (x, y) co-ordinates relative to an orientation 
mark in the bottom left hand corner of the sample. The FTIR spectrometer had an 
inbuilt (x, y) measurement facility enabling FTIR targeting of specific areas for spectral 
measurements.   
   
2.1.5 TURP, Prostate biopsy and Radical Prostatectomy Specimens: Exclusion 
criteria for FTIR analysis 
 
1) H & E sections had to be of sufficient quality to allow precise histological 
classification which could be compared with FTIR sample analysis – where 
classification could not be performed the sample was excluded 
2) Following cold cryotome sectioning, consecutive sections needed to be 
comparable to allow histological mapping – where this was not the case the 
sample was excluded 
3) Specimens which were damaged or uneven and therefore would not allow good 
quality FTIR spectra to be collected were excluded from the study.  Where 
possible adjacent consecutive specimens were analysed. 
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2.2 Prostate Tissue Fixation 
The aim of fixation is to maintain the form and structure of tissue elements in a 
condition as close to in vivo as possible. Prostate specimens obtained by TURP, TRUS 
biopsy and radical prostatectomy are routinely fixed in formalin prior to histological 
analysis in clinical practice today.  Without fixation, once the prostate tissue is removed 
from its blood supply autolysis (the enzymatic digestion of cells by the enzymes 
contained within them) and movements in intracellular water molecules will occur. 
Both of these factors may cause destruction of normal intracellular structures and 
biochemistry and thus may limit the value of FTIR analysis. In the studies which follow 
two methods of cell fixation have been used; flash freezing (for the biopsy and TURP 
specimens) and formalin fixation followed by paraffin embedding (for the radical 
prostatectomy specimens). 
 
2.2.1 Flash Freezing of Prostate Tissue 
Prostate tissue is hydrated when in vivo; when chemical reagents are used to preserve 
tissue their interactions to achieve dehydration invariably affect tissue biochemistry. 
Liquid nitrogen emersion of a sample within a cryo-vial enables a small specimen to be 
completely frozen in less than a second. The speed of freezing reduces the likelihood of 
intracellular ice crystal damage and preserves tissue biochemistry. Although studies 
have demonstrated in other tissues that freezing followed by drying may cause artefacts 
such as chemical migration and reduction in frozen cell size. Specifically in the prostate 
however, FTIR studies have demonstrated that valid spectra can be obtained from 
prostate cells or tissue which has been flash frozen1,2. The unstained frozen sections 
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used in this work were removed from the freezer and allowed to defrost and air dry for 
at least one hour prior to FTIR analysis. 
2.2.2 Formalin Fixation of Prostate Tissue 
Although many chemical fixatives exist, formalin is used universally in clinical practice 
for prostate and the radical prostatectomy specimens detailed in this thesis. Formalin 
fixation in radical prostatectomy specimens is necessary to determine the margin status, 
tumour volume and grade in routine histological practice3. The standard buffered 
formalin fixative is an aqueous solution containing formaldehyde 37% and methyl 
alcohol 10-15%. Formalin is a highly reactive dipolar compound that forms protein - 
nucleic acid and protein – protein crosslinks in vitro. Glycogen and lipids are also 
preserved by this process. Formalin fixation is followed by paraffin embedding in 
routine histological practice prior to haematoxylin and eosin staining and examination 
using white light microscopy4. Depending on the size of the gland, formalin fixation at 
Gloucestershire Royal Hospital takes at least 48 hours, followed by a further 24 hours 
for further processing and paraffin embedding. Although formalin fixation is a 
relatively simple process which provides superior morphological detail and consistency, 
it is time consuming and its limitations with respect to the potential effects of fixative 
cross linkage on molecular studies are acknowledged. 
 
2.2.3 Preparation of Radical Prostatectomy Specimens for FTIR Analysis 
Radical prostatectomy specimens were removed at operation, placed in buffered 
formalin and transferred to the pathology department at Gloucester Royal Hospital. All 
prostate specimens were prepared in a similar fashion. Formalin fixation of the 
specimen for a minimum of 48 hours was allowed. The specimen then underwent ‘cut 
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up’ by a pathologist. At ‘cut up’ the prostate was weighed, orientated and its dimensions 
measured. Macroscopic examination of the prostate specimen was performed. The 
external surface of the prostate was then marked with different colours (for example red 
for right, blue for left and green for base) to ensure orientation after further processing. 
The gland was sliced in 5mm intervals from apex up and laid in clearly labelled, 
consecutive individual cassettes, called blocks. The prostate sections in the blocks were 
then dehydrated in graded alcohols, cleared in xylene and embedded as flat as possible 
in paraffin wax using a processor and left to set. The Royal College of Pathologists 
prostate minimum dataset guidelines were adhered to in all processing steps. 10 μm 
sections were then harvested from selected blocks using a microtome. Consecutive 
sections were taken for histological and FTIR analysis respectively to enable mapping 
of pathology (Figures 2.4 and 2.5 respectively). To achieve deparaffination, sections 
were placed in a xylene bath followed by a warm water bath. Specimens were mounted 
on calcium fluoride slides and air dried prior to FTIR analysis. Sections for histological 
analysis were H & E stained. 
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 Figure 2.4 Haematoxylin & eosin stained radical prostatectomy section 
 
 
Figure 2.5 White light image of unstained prostate section corresponding to above 
H&E section for FTIR analysis 
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2.3 Fourier Transform Infrared Spectroscopy 
2.3.1 Instrumentation 
Prostate specimens were analysed using a Perkin Elmer® Spotlight 300 Fourier 
Transform Infrared Spectroscopy system in a temperature and humidity controlled 
laboratory (see Figure 2.6). The system consists of a liquid nitrogen cooled single point 
100 x 100μm2 mercury-cadmium-telluride (MCT) detector and 16 x 1 element (400 x 
25 μm2) MCT array detector for image and single point measurements. Resolutions 
achieved by the single point MCT by the MCT array detectors are 25 and 6.25 μm 
respectively. The spectral range covered by the array and single point detector are 7800 
to 720cm-1 and 7800 to 580 cm-1 respectively. The spectrometer is attached to a 
microscope equipped with a CCD camera and white light LED illumination in order to 
view optical images of the sample. The x-y-z stage with sample holder was 
programmable. White light images could be collected together to construct map images. 
The aperture of the instrument to focus infrared light onto the sample and the cassigrain 
to collect the infrared light transmitted through the sample are adjustable. Settings for 
the FTIR studies are described below. On start-up of the FTIR spotlight spectrometer, 
calibration, stage and motor checks are performed automatically. Prior to measurements 
the liquid nitrogen cooled detector was filled with liquid nitrogen, the spectrometer 
ensured that sufficient energy was available to perform the studies and an alert warning 
informed the user if refilling of the detector was required to continue recording data. 
Background scans from a blank area of calcium fluoride were performed prior to all 
data acquisition and ratioed against the sample spectrum. 
 98
 Figure 2.6 Perkin Elmer® Spotlight 300 FTIR Spectroscopy System 
 
2.3.2 Settings for Mapping Measurements of Prostate Specimens 
The term mapping describes the process of obtaining the spectral / biochemical 
equivalent of the visual representation obtained at microscopic analysis of tissue. Air 
dried or preserved prostate tissue specimens, mounted on calcium fluoride were placed 
on the silver sample holder and positioned on the stage. The software settings were set 
to image mode, FTIR spectra were measured in transmission mode, 8cm-1 wavelength 
resolution, 25 μm pixel resolution (interval steps), 16 co-scans per pixel and wavelength 
range of 4000-720cm-1. The mapping studies analysed areas of specific interest guided 
by histological analysis of the adjacent haematoxylin and eosin stained consecutive 
section. The white light mode and video capture from the microscope enabled the 
appropriate positioning of the sample for interrogation.  Map measurements were 
guided and recorded as number of steps in both the x and y direction across a specimen. 
The size of the map measured was limited by time constraints firstly to perform a map 
 99
using the above settings and secondly the duration of cooling conferred by the liquid 
nitrogen in the detector. A complete fill allowed for typically 8 hours of measurements. 
It was not possible to examine an entire large radical prostatectomy specimen without 
running out of liquid nitrogen in the detector.  Therefore the primary method used was 
to split the analysis of large specimens into size-compatible portions. The possible 
method of refilling the detector with liquid nitrogen during measurements was 
examined in the larger radical prostatectomy specimens’ analysis. On completion the 
intensity *.imp file, white light image *.vw and spectral map *.fsm data were saved on 
to the computer attached to the spectrometer. Hyperview® software enabled the map 
parameters to be viewed. The *.fsm map file was converted into an ASCII *.dat map 
file containing the transmittance and wavenumbers for each map. Matlab® programs 
designed in house by Dr Nick Stone were used to perform data processing: as described 
in section 2.3.4. 
 
2.3.3 Settings for Point Measurements 
Air dried or preserved prostate tissue samples, mounted on calcium fluoride, were 
analysed using the spectrometer in point mode, in transmission. The radical 
prostatectomy specimens were mapped in their entirety. Due to the constraints of the 
liquid nitrogen cooled detector the specimen was divided into smaller sections for 
manageable point maps (Illustrated in figure 2.7). The specimens were not removed 
from the stage until complete analysis had been performed. The effect of altering the 
spectral resolution, aperture and number of co-scans per pixel were explored in point 
map radical prostatectomy studies. Wavelength range was 4000-720cm-1. When 
targeted point spectra were taken from specific pathologies, ten selected spectra were 
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taken from each pathology present within a sample (Figure 2.8). Spectral files were 
saved to the computer attached to the spectrometer. The point maps of the radical 
prostate sections were converted from *.fsm files to ASCII *.dat map file in a similar 
fashion as in section 2.2.2 above.  The mean spectra from point spectra taken from 
selected pathology areas was analysed, compared and contrasted and will be discussed 
in the following results chapters. Matlab® programs designed in house by Dr Nick 
Stone were used to process the data: described in section 2.3.4. 
 
 
Figure 2.7 White light image illustrating methodology in point mapping of radical 
prostatectomy sections 
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 Figure 2.8 White light image demonstrating targeting of point spectra (marked 
with a cross) enabling measurement of specific areas of interest 
 
2.3.4 Data Processing 
Matlab® was used to load the spectral data from the ASCII map file and generate 
Principle Component Analysis (PCA) pseudo-colour maps (Illustrated below in figures 
2.9 and 2.10). During the map loading process the spectra were interpolated to 4cm-1 
wavenumber spacing, converted to absorbance using (log(max(transmittance))-
log(transmittance)), where transmittance = Iout/Iin and smoothed using Savitzky-Golay 
(polynomial) to remove noise. The data was represented within Matlab® as a 3D 
matrix. The PCA score maps were compared to the white light image and H & E slide. 
A Matlab® script allowed regions to be selected from the pseudo-colour maps and 
labelled as to their appropriate pathology. Mean spectra from these pathologies could 
then be plotted and interrogated as described below. 
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 Figure 2.9 White light image of selected area of interest in prostate TURP section 
 
Figure 2.10 PC score pseudocolour map corresponding with above white light 
image, the red squares illustrate how specific regions may be selected 
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2.4 Data Analysis 
Visual spectral interpretation has formed the backbone of spectroscopic analysis since 
the establishment of spectrometers but may be highly subjective, particularly in modern 
spectroscopy, where a huge amount of spectral data is collected by FTIR focal plane 
array detectors. Pattern recognition techniques are applied to infrared data, which 
attempt to remove subjectivity and allow realistic processing of large datasets. The 
choice of analysis technique is dependent on the samples’ spectral characteristics and 
individual group preference for data analysis software.  
 
2.4.1 Peak Position / Peak Height / Peak Area 
Peak position can be correlated with known verified tables of key functional group 
absorbance peak positions. Differences in key functional group may be observed 
between pathologies. Peak height and area correspond to relative concentration of 
constituents. Analysis of peak intensity ratios can be the most straightforward way of 
identifying concentrations and locations of different substances as long as the 
component groups can be easily distinguished. Peak intensity ratios may enable 
differentiation between pathologies either from directly comparing single peak 
intensities between samples or establishing the ratio between key peaks within one 
sample and then comparing this ratio with other pathologies in separate samples. 
 
2.4.2 Multivariate Analysis 
Multivariate analysis enables the majority of the data within an infrared spectrum to be 
utilised and is especially useful in determining and separating subtle differences in 
pathology groups under examination. Multivariate analysis is necessary in tissue 
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diagnostics because it permits simultaneous analysis of multiple independent and 
dependent variables present in the spectral dataset. This analysis may be supervised or 
unsupervised. In this thesis because histological analysis allows us to know the 
pathologies within a sample and their location when we attempt to associate the 
pathology groups with the inputted spectral dataset this is termed supervised analysis. 
Unsupervised analysis describes when input values are analysed on the basis of the 
differences between them within the dataset without external interference. The 
multivariate analysis employed to construct the diagnostic algorithms in this thesis was 
primarily principal component-fed linear discriminant analysis. Principal component 
analysis (PCA) is applied to the spectral dataset to compress the data without losing 
relevant information. PCA is unsupervised. Linear discriminant analysis (LDA) then 
accentuates the differences between groups in spectral morphology. LDA is supervised. 
PCA fed LDA can produce a diagnostic algorithm or model which can be tested. The 
sensitivity and specificity of this algorithm in determining pathologies can be evaluated. 
The following sections will describe these techniques in detail. 
 
2.4.3 Principal Component Analysis (PCA) 
Principal component analysis calculates principal components (PCs) from the spectral 
dataset. These PCs are also known as loads and describe the greatest variance of 
spectral data from its mean. The first PC load describes the maximum variance and the 
second the next highest, progressively decreasing accordingly. As PCs are 
representations of the original spectra, spectra may be reconstituted by multiplying the 
loads by a variable termed PC scores.  Thus spectra may be represented by either loads 
or scores. Using PC score data for analysis reduces the number of variables / data 
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needing to be processed within a dataset whilst retaining the spectral information, 
allowing each spectrum within the sample to be compared. Depending on the degree of 
variance of the sample under investigation the number of PC scores used is decided and 
the loads for the dataset were always retained. 
 
PCA also allows co-linear spectral variations to be considered together. Infrared spectra 
of tissues have multiple characteristic peaks corresponding to concentration of 
substances present. Changes in the concentrations of these substances may cause 
changes in the heights of peaks within the whole spectrum. Loads can therefore reflect 
significant changes in the concentration of a substance by resembling the substance 
spectra. This allows valuable insight into the important molecular differences which 
exist between different pathologies.  
 
PCA can be visualised in multiple ways as will be demonstrated in the Results chapter 
later. PCA pseudo-colour images of the sample under investigation can also be created 
by giving each score a colour rating. Each colour then represents the score of that 
component at each position where that spectrum was measured. 
 
2.4.4 Linear Discriminant Analysis (LDA) 
Linear discriminant analysis (LDA) is a technique used to improve the clustering of 
different pathological groups. In the context of this study, LDA takes into account the 
different variables (scores) determined by PCA and works out which pathological group 
the spectrum with that value is most likely to belong to. LDA in combination with PCA 
acts to maximise the variance in the data between pathological groups and minimize the 
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variation within a group. PCA ensures the LDA requirement, that the number of input 
variables (spectral wavenumbers) is less than the number of spectra in the dataset. LDA 
is supervised because it requires information as to how spectra are classified, 
specifically the pathological diagnosis which is input by the spectroscopist. PCA fed 
LDA was used to construct diagnostic algorithms for pathology groupings in this study. 
The algorithms were tested as to their accuracy.  
 
2.4.5 Testing the Diagnostic Algorithm 
The algorithms were tested using a ‘leave one sample out’ cross validation and using a 
separate population of test spectra.  
 
‘Leave one sample out’: A testing protocol is established where a diagnostic algorithm 
is established leaving the spectra from one sample out of the model and then testing the 
algorithm using the spectrum not included in constructing the algorithm. The advantage 
of this technique is that when the number of test spectra / more importantly sample 
number is low it allows the algorithm to be tested. 
 
Using test spectra population: In this thesis a test spectra group was created from 
separate samples and the algorithm tested using this separate group. The spectra were 
obtained from fresh frozen prostate biopsy and TURP samples. The effect of different 
sampling methods will be discussed in the next section. 
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2.4.6 Parametric Non-negative Least Squares Fitting  
This thesis will explore the application of parametric non negative-least squares fitting 
to describing and investigating possible biomarkers for prostate cancer. ‘Least squares 
fitting’ describes the technique of applying a best fit curve to a given number of points. 
This is performed on measured tissue spectra by: identifying the most likely dominant 
component constituents of the tissue; measuring the pure spectra of these components 
and then attempting to match the spectra in various combinations to the tissue spectra. 
The aim is to get a perfect fit with no residual. Residual describes the offset of the fitted 
curve from the actual spectra. This will be discussed later in this thesis. 
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“ What we anticipate seldom occurs; what we least expect generally happens. ” 
Benjamin Disraeli 1804 - 1881 
3 Results 
 
This chapter describes the analysis of the spectra recorded on the FTIR spotlight 
system. The sub-sections deal with progressive investigation of the different prostate 
specimens under investigation. 
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3.1 Preliminary Study of Prostate Tissue from 
TURP 
The purpose of this study was to determine whether FTIR image mapping could 
differentiate between benign and malignant prostate pathology. Specific areas of known 
pathology selected in concordance with the pathologists’ observations within fresh 
frozen prostate chippings were analysed by FTIR. Figure 3.1 overleaf illustrates the 
process of how FTIR images were obtained from each sample. 
 
TURP chips were obtained from fifty patients, of which 27 patient samples were 
suitable for FTIR analysis.  The sections were imaged in transmittance mode with a 
pixel size of 6.25μm. 203,629 spectra were obtained from the 27 samples. Total scan 
time 2327 minutes.  Selected spectra from histologically classified benign and 
malignant areas of epithelial and stromal tissue were then taken from PCA score maps. 
 
 Benign prostate tissue Malignant prostate tissue 
Number of patients 23 4 
Number of samples 23 4 
Number of spectra 7141 5168 
 
Table 3.1 Breakdown of samples measured by FTIR
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Figure 3.1 The process by 
which FTIR images of areas of 
interest are obtained 
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 Unstained corresponding section 
 
 FTIR pseudocolour image map of area of interest 
H & E section from TURP chip 
 Although specific region selection was performed there was variability between the 
spectra collected, shown in figure 3.2. Part of this variability was expected because of 
differences between the pathology analysed, however a proportion of the variability 
results from the mapping process. There will be gaps between cells and the tissue in 
addition to external potential contaminants. This does not affect the majority of the 
spectra or the ability of the spectra to be used to discriminate between pathologies. It is 
possible to remove the spectra of concern when composing the model by a process of 
normalisation to exclude the spectra at extremes. 
3.1.1 TURP Spectral Data 
Figure 3.2 Total selected spectra from benign and malignant pathologies 
Figure 3.3 Normalised spectra from benign and malignant pathologies 
113
 
Absorbance 
Absorbance 
Wavenumber (cm-1) 
Wavenumber (cm-1) 
 
Figure 3.3 illustrates the normalised spectral data. The data has been processed by 
removing the minimum value from all the spectra, thus making all spectra positive and 
using the amide region to ensure all the relevant spectra have been kept. The mean 
spectra from each pathology group was also calculated, and is shown in Figure 3.4. 
 
 
Figure 3.4 Mean spectra from benign (BPH) and malignant (CaP) pathologies 
 
3.1.2 Analysis of Peak Absorbance Ratios 
Although at first glance benign and malignant mean spectra appear identical in shape, 
for example similar peaks at 1456cm-1, 1550cm-1 and 1660cm-1, closer inspection 
reveals subtle differences. An extra peak in benign tissue at 1634cm-1, a less prominent 
peak at 1403 in benign tissue and an extra peak in malignant tissue at 1317cm-1is 
observed. Table 3.2 illustrates the potential biochemical differences between the 
pathologies on the basis of known peak assignments. 
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Biomolecule 
 
Bond Vibration Wavenumber 
(cm-1) 
References 
Amide I 
(random coil ~) 
H bonded amide / 
peptide 
groups 
1652-1695 
(α-helix ~1655) 
(β-sheet ~1637) 
Neviliappan et al 20021 
Beleites et al 20052 
Erukhimovitch et al 
20053 
Jackson et al 19954 
Diem et al 20005 
Proteins 
 
 
CH3 (methyl) 
CH2 (methylene) 
1400 
1450 
Neviliappan et al 20021 
Sule-Suso et al 20056 
Schultz et al 19967 
Carbohydrates 
(e.g. glycogen) 
 
C-O stretch 
C-OH bend 
C-OH stretch 
 
1200-900 
1025 
1047 
1085 
1155 
(1000-1190) 
Neviliappan et al 20021 
Erukhimovitch et al 
20053 
Lasch et al 20028,9 
 
Table 3.2 Referenced known infrared peak assignments corresponding to mean 
spectra differences between pathology groups 
 
3.1.3 Multivariate Analysis 
Multivariate analysis in the form of PCA fed linear discriminant analysis was applied to 
the spectral dataset as discussed in section 2.4. For each FTIR map analysed, ten 
principal components were calculated. The loads and scores were observed; see 
example in figure 3.5. The loads, which describe the variance from the mean of the 
dataset, reflect changes in molecular concentration of the substance. If significant 
differences in concentration are present, the loads may actually represent the spectrum 
of the substance which has changed. The score maps, which reduce the data needed to 
be processed, are a good representation of the tissue under analysis. 
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PC Loads 
 
White light image 
Figure 3.5 – PC scores 
and loads for a single 
prostate section analysis
PC Score maps  
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Linear discriminant analysis uses a linear discriminant function to maximise the 
distance between groups but minimise the distance between group members. The 
histogram in figure 3.6 below illustrates the degree of separation between benign and 
malignant pathologies achieved by PCA linear discriminant analysis. 
 
 
 
 
 
 
 
Number of spectra 
Linear Discriminant Analysis 
CaP 
BPH 
The predicted performance of the two group model created by the included spectra 
can also be demonstrated in tabular form (table 3.3).  The sensitivity and specificity of 
the algorithm may be determined from this. The sensitivity is the number of spectra 
from the pathological group correctly predicted to be in the right group (true 
positives). The specificity of the group is the number of spectra correctly identified as 
not belonging to the group (true negatives). The two group model sensitivity was 97% 
and the specificity was 90%. 
 
Figure 3.6 Histogram illustrating separation achieved between benign and 
malignant tissue with PCA fed Linear Discriminate Analysis 
 
 
  
FTIR Algorithm-predicted diagnosis (number of spectra) 
 
  
Benign 
 
 
Malignant 
 
Benign 
 
 
6909 
 
232 
 
 
Histological 
Diagnosis 
(number of 
spectra) 
  
Malignant 
 
499 
 
 
4669 
 
Table 3.3 Results achieved by two group algorithm: benign versus malignant 
tissue 
 
3.1.4 Expansion of the Diagnostic Algorithm Groups 
The pathology groupings for the primary analysis were benign and malignant tissue 
only, based on the rationale that the pathologies were clear and that the individual 
patient sample number was relatively low. Once the results discussed above were 
realised, the concept of more in depth analysis of tissues was explored. Sub-
classification of benign prostate tissue into epithelial tissue, ductal tissue and stroma 
in benign tissue was investigated. Sub-classification of malignant prostate tissue into 
adenocarcinoma (glandular and ductal areas) and cancerous stroma (surrounding 
cancer cells) was investigated. The tables which follow summarise the models 
performance. The key finding from a pathology perspective was the stromal analysis 
(tables 3.4 and 3.5); usually pathologists are unable to gain a significant amount of 
information from prostate stromal tissue, however PCA fed linear discriminant 
analysis elicits a clear distinction between stromal tissue related to benign tissue and 
stromal tissue related to malignant tissue. 
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Algorithm-predicted diagnosis (number of spectra) 
 
 Benign Stroma Malignant 
Stroma 
Total No 
Spectra 
Benign Stroma 
 
1500 1 1501 
 
Histological 
Diagnosis 
(number of 
spectra) Malignant 
Stroma 
4 679 683 
Sensitivity = 99.93; Specificity = 99.41 
Table 3.4 Results achieved by two group algorithm: benign versus malignant 
stroma 
 
  
FTIR Algorithm-predicted diagnosis (number of spectra) 
 
 BPH Benign 
stroma 
CAP Malignant 
stroma 
BPH 
 
3072 770 32 119 
Benign 
stroma 
194 1239 0 68 
CaP 
 
133 3 787 139 
 
 
 
Histological 
Diagnosis 
(number of 
spectra) 
Malignant 
stroma 
22 54 10 597 
 
Table 3.5 Results achieved by four group algorithm 
 
In the four group model, percentages of spectra allocated correctly for BPH, benign 
stroma, CaP and malignant stroma were 76.93%, 82.55%, 74.11% and 87.41% 
respectively (see table 3.5).  
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FTIR Algorithm-predicted diagnosis (number of spectra) 
 
 Benign 
Ductal 
BPH Benign 
Stroma 
CAP Malignant 
Ductal 
Malignant 
Stroma 
Benign 
Ductal 
1385 142 2 16 0 1 
BPH 
 
465 2726 617 10 75 100 
Benign 
Stroma 
79 202 1166 0 1 53 
CaP 
 
18 94 0 765 55 130 
Malignant 
Ductal 
12 22 6 5 254 67 
 
 
 
 
Histological 
Diagnosis 
(number of 
spectra) 
Malignant 
Stroma 
0 38 29 9 0 607 
 
Table 3.6 Results achieved by six group algorithm 
 
In the six group model, percentages of spectra allocated correctly for Benign ductal 
tissue, BPH, benign stroma, CaP, malignant ductal tissue and malignant stroma were 
89.59%, 68.27%, 77.68%, 72.03%, 69.40% and 88.87% respectively (see table 3.6).  
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3.1.5 Cross Validation of Diagnostic Algorithms  
‘Leave one sample out’ cross validation was used to evaluate the diagnostic 
algorithm. The testing protocol removed all the spectra of one sample from the 
diagnostic algorithm and used the removed spectra to test the algorithm. The process 
was repeated for all samples. This method is rigorous because the test spectra are not 
included in the constructed diagnostic algorithm. It is slightly less scientifically robust 
than evaluating the diagnostic algorithm with a large test cohort of new samples, 
however this method of analysis enables algorithm testing when the sample numbers 
are relatively low. The result of cross validation for benign versus malignant tissue 
spectra is illustrated in the table 3.7 below:  
  
FTIR algorithm-predicted diagnosis (number of spectra) 
 
 Benign Malignant Total No 
Spectra 
Benign 
 
3822 198 4020 
Malignant 
 
292 2362 2654 
 
 
Histological 
Diagnosis 
(number of 
spectra) 
Total no. of 
Spectra 
4114 2560 6674 
Sensitivity = 95%; Specificity = 89% 
Table 3.7 Cross validated results for two group algorithm benign versus 
malignant tissue spectra 
 
3.1.6 Commentary on Results from Preliminary TURP Study 
This preliminary study demonstrated that FTIR was able to interrogate prostate tissue 
and by analysis of FTIR spectra it was possible to discriminate between benign and 
malignant prostate pathology. The potential of FTIR to obtain useful biochemical 
information from all tissue under investigation including areas not normally utilised 
by the pathologist was also realised.  
 121
 The limitations of the technique and the study were also recognised:- 
• Small sample number 
• The potential confounding effect of diathermy on TURP tissue biochemistry 
• The lack of a study control to account for differences between samples 
• How to determine true biochemical changes within samples 
• FTIR analysis had been performed only on fresh frozen tissue 
• The considerable time  required to FTIR map even small samples  
 
These thoughts stimulated the progression of the study to use FTIR to analyse radical 
prostatectomy sections in their entirety to address the aforementioned issues. 
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3.2 Study of Prostate Tissue from Radical 
Prostatectomy 
The purpose of the studies which follow in this section of the thesis were to evaluate 
the clinical potential of FTIR as a pathology classification tool by performing detailed 
analysis of radical prostatectomy specimens. The concept of point mapping was 
explored and related to formal FTIR mapping; the ability of FTIR to discriminate 
between pathologies within prostate specimens and between different prostate 
specimens was examined. The sections were able to act as their own controls in 
pathology studies as each contained multiple pathologies. Prostate sections were 
analysed in paraffinated and deparaffinated forms to examine whether spectral 
information was lost in the deparaffination process and inform the potential clinical 
application of the technique. The reproducibility of measurements was also assessed. 
Prostatic Intraepithelial Neoplasia was also interrogated by FTIR and its spectra 
analysed for the first time in such tissue studies. 
  
3.2.1 Point Map Analysis of Radical Prostatectomy Sections 
Initially, five radical prostatectomy sections were analysed in their entirety using the 
point map technique in both their paraffinated and deparaffinated forms. Table 3.8 
describes the data collected from each sample. Figure 3.7 illustrates the point mapping 
process. The step size interval (the distance between each point measurement) was 
calculated to allow measurement of equal sections of the prostate, each within the 
eight hour time constraint of effective detector function after filling with liquid 
nitrogen. Areas were measured using the microscope ruler. Spectra were obtained in 
point mode, transmission, spectral resolution 4cm-1, 16 co-scans, aperture size 100μm 
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x 100μm and wavelength range 4000-720cm-1. Background scans were taken prior to 
each measurement. 
 
Radical 
prostatectomy 
specimen 
Step size 
interval 
(microns) 
Number of 
composite 
sections 
Total 
section 
dimensions 
x:y (mm) 
Total 
number of 
spectra 
collected 
Pathologies 
present 
1 500 3 42:25.5 4350 BPH, 
Prostatitis, 
PIN, 
Gleason 
3+4=7 CAP
2 700 4 45.5:32.2 3243 BPH, 
Gleason 
4+4=8 CAP
3 700 4 56:35 4074 Benign 
tissue, 
Gleason 
3+3=6 CAP
4 500 5 42:40 7209 PIN, 
Gleason 
4+3=7 CAP
5 600 4 47.4:42 5893 BPH, 
Gleason 
3+4=7 CAP
 
Table 3.8 Breakdown of data collected from prostate sections 
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 Radical 
prostatectomy 
specimen 
Urethral catheter, 
left in situ post 
operation to 
orientate specimen 
Radical Prostatectomy Specimen 1
 
 
 
 
 
 
 
Figure 3.7 The point mapping process 
Corresponding unstained 10 micron 
section for FTIR analysis, crosses on grid 
illustrate where spectra were taken from 
Transverse H&E stained 10 micron 
section, after pathological analysis 
Prostatic calculi and 
surrounding prostatitis 
BPH 
PIN Urethra Prostate 
Cancer 
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Figure 3.8 Region selection in prostatectomy section one from pseudocolour PCA 
score map 
 
3.2.2 Radical Prostatectomy Five Section Specimen Spectral Analysis 
The point maps were zipped together using Matlab® software and converted into 
pseudocolour PCA score maps representative of the sections under analysis in a 
similar manner to that described in section 3.1. Region selection of specific spectra 
from identified pathologies was then performed. Figure 3.8 illustrates the region 
selection process in the large prostate sections. The spectra then underwent 
normalisation and mean spectra for the pathologies under analysis were produced for 
the individual sections alone and the cohort of five sections in both paraffinated and 
deparaffinated form. 
 
Using prostate section four as an example, this section contained benign and 
malignant prostate tissue in addition to PIN, in clearly demarcated areas. The mean 
spectra of the pathologies from section four in paraffinated and deparaffinated forms 
are shown in figures 3.10 and 3.11 respectively. 
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The first important observation is that excellent spectra may be obtained from both 
paraffinated and deparaffinated prostate sections. The paraffin peak is evident at 
approximately 1460cm-1 in the paraffinated sections and not when the same section 
has been deparaffinated. Although the paraffin peak obscures the tissue peak at 1460 
it does not seem to interfere with or prevent interpretation of absorbance at other 
wavenumbers. The second finding was that the spectral morphology seemed more 
distinctive when prostate tissue was analysed in its paraffinated form. Similar changes 
in spectral morphology are evident between benign and malignant prostate tissue as 
determined in the analysis of fresh frozen TURP chippings (section 3.1). There are 
peak ratio differences between different prostate pathologies in the Amide I region. 
Benign tissue has an additional peak at 1440cm-1. At approximately 1440cm-1 CaP 
has a prominent distinctive peak which is less prominent in benign tissue. The mean 
spectra of PIN has similar morphology to CaP. These findings were mirrored in all 
sections.  
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 Absorbance 
Wavenumber (cm-1) 
Figure 3.10 Mean spectra from pathologies in paraffinated section four 
 Figure 3.11 Mean spectra from pathologies in deparaffinated section four 
Absorbance 
Wavenumber (cm-1) 
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Having determined clear distinction between the spectra of pathologies in 
heterogeneous individual prostate sections, the pooled mean spectra for all samples 
were then examined. The deparaffinated dataset is used to illustrate this in figure 3.12, 
the paraffin and CaF2 spectra have not been included. The findings were almost 
identical to the individual section findings. 
 
Figure 3.12 Analysis of mean spectra from all pathology groups from five 
sections 
 
 
3.2.3 Multivariate Analysis of the Five Section Spectral Dataset 
 
Principle component fed linear discriminant analysis was performed on the selected 
spectra. The degree of separation achieved for benign, malignant prostate tissue and 
PIN is illustrated in figure 3.13. The sensitivities and specificities achieved by the 
three pathology group model are described in table 3.9. 
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Pathology Benign  Prostate Cancer PIN 
FTIR Sensitivity 
(%) 
82 85 80 
FTIR Specificity 
(%) 
87 84 96 
 
 
Table 3.9 Sensitivities and specificities of the three pathology group algorithm 
 
 
Figure 3.13 Scatter plot illustrating linear discriminant analysis of pathologies  
 
 
 
3.2.4 Evaluating Why Discrimination of Pathologies May Not Be Perfect 
Although the above model achieved reasonably good classification of the main 
pathologies, an obvious critique is why is the classification not perfect? One 
hypothesis may be that individuals’ prostate cancer might differ biochemically. This 
might be accounted for by differences in Gleason grade between individuals, however 
before this theory may be explored further it was necessary to ascertain whether 
differences between cancers exist within a specimen. Three of the nine radical 
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prostatectomy sections used in this thesis contained multifocal tumours, allocated 
with the same Gleason grade within the specimen. The mean spectra from each area 
were compared. Radical prostatectomy specimen six and seven are used to illustrate 
these results. 
 
 
Figure 3.14 Prostatectomy section six: H & E stained section with two areas of 
Gleason 3+4=7 prostate cancer 
 
Figure 3.15 PC score map of prostatectomy section six: Region selection of two 
areas of Gleason 3+4=7 prostate cancer (mapped from H & E stained section in 
Figure 3.14 above) 
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 Absorbance 
 
Wavenumber (cm-1)
Figure 3.16 Mean spectra from two separate Gleason 3+4 areas in prostatectomy 
section six 
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Absorbance 
Wavenumber (cm-1) 
Figure 3.17 Mean spectra from two separate Gleason 3+3=6 areas in 
prostatectomy section seven 
 
Figures 3.16 and 3.17 show the mean spectra of two areas of prostate cancer, of the 
same Gleason grade, exhibiting different mean spectra, in prostatectomy sections six 
and seven. 
 
3.2.5 Cross Validation of Three Group Model 
‘Leave One Sample Out’ Cross Validation of the three group model was performed 
for deparaffinated radical prostatectomy sections one to five. The performance of the 
algorithm is shown below in table 3.10. The percentages predicted correct for Benign, 
Cancer and PIN pathologies were 77%, 88% and 91% respectively. The overall 
training performance of the model was 83.16%; the prediction performance was 
24.62%. 
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FTIR algorithm-predicted diagnosis (number of spectra) 
 
 Benign Cancer PIN Total 
number of 
spectra 
Benign 
 
366 76 36 478 
Cancer 
 
27 396 27 450 
PIN 
 
7 3 107 117 
 
 
 
 
Histological 
diagnosis 
(Number of 
spectra) 
Total 
number of 
spectra 
400 475 170 1045 
 
Table 3.10 Leave one sample out cross validation results for three group model in 
prostatectomy sections one to five 
 
Blind Test Group Validation of the three group model was then performed by 
projecting the data from radical prostatectomy specimens six to nine onto the above 
prostatectomy sections’ three group model, as a test group.  Findings are shown in 
table 3.11. The percentages predicted correct for Benign, Cancer and PIN pathologies 
were 28%, 13% and 91% respectively. 
 134
 
  
FTIR algorithm-predicted diagnosis (number of spectra) 
 
 Benign Cancer PIN Total 
number of 
spectra 
Benign 
 
101 46 208 355 
Cancer 
 
40 44 245 329 
PIN 
 
2 1 32 35 
 
 
 
 
Histological 
diagnosis 
(number of 
spectra) 
Total 
number of 
spectra 
143 91 485 719 
 
Table 3.11 Blind test group validation of the three group model 
 
 
3.2.6 Commentary on Results from Point Map Analysis of Radical Prostatectomy 
Sections 
The results from point mapping of the specimens so far reinforce the hypothesis that 
FTIR may have a role as a potential histological classification tool. FTIR has 
differentiated between pathologies within the same specimen and in multiple 
specimens. It has been demonstrated that stain free biochemical imaging is possible of 
both paraffinated and deparaffinated specimens. Therefore practically this may have 
application as in practice it could remove the need for and time taken for processing 
steps. The spectra of PIN has been classified as an entity, and is similar in 
morphology to CaP, but more importantly is identifiable as a distinct pathology from 
benign and malignant tissue.  Point mapping, as a concept, allows a greater proportion 
of the tissue to be imaged and enables adequate spectral data collection of 
pathologies. The point mapping of entire sections has enabled the evaluation of 
heterogeneous tumours and their differences. The effect of TURP diathermy does not 
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appear to have a significant effect on prostate tissue biochemistry as the same spectral 
differences have been elicited in both TURP and Radical Prostatectomy tissue. 
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3.3 FTIR System Validation Experiments 
In clinical practice, point mapping of specimens would appear to be the ideal method 
to allow high throughput of samples with in depth image mapping reserved for 
specific areas of interest. The immediate concern regarding the point map technique is 
whether pathology would be missed by critical step size interval. In addition to this, 
knowledge with respect to the reproducibility of the technique is also important if 
FTIR is to have a clinical application. These issues were addressed in technique 
validation studies which are described in this section. 
 
 
3.3.1 Point Map Validation Studies  
The purpose of the studies in this section are to investigate the reproducibility of 
biochemical analysis achievable by the FTIR system; the effect of number of co-scans 
on the biochemical data obtained by FTIR; and finally evaluate the effect of step size 
on the detail of the biochemical data obtained by FTIR from prostate pathologies. 
Radical prostatectomy sections six and eight were used for this analysis. 
 
3.3.2 Reproducibility of the System 
These studies were performed on section eight which contained three pathologies: 
Cancer, Benign tissue and PIN. The aim was to establish whether the FTIR system 
analysis of pathologies were reproducible over a three day period. Each pathology 
was examined three times within a 24 hour period and subsequently at 24 hour 
intervals over a three day period. The specimen under analysis was not removed or 
repositioned between measurements. For each pathology, twenty targeted point 
spectra (see figure 2.8) were taken at each measurement and measurements were 
repeated three times each time the pathology was examined. If t = time of first 
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measurement, the time of measurements in hours were: (t), (t+1), (t+12), (t+24), 
(t+48), (t+72). The software settings were set to: point collection mode, transmission 
mode, aperture 30μm x 30μm, 1cm-1 spectral resolution, 75 number of co-scans / 128 
number of co-scans. The mean spectra obtained at (t) and (t+12) for PIN is illustrated 
in figure 3.18, the mean spectra obtained at (t+24), (t+48) and (t+72) for benign tissue 
are illustrated in figure 3.19. 
 
Absorbance 
Wavenumber (cm-1) 
Figure 3.18 Mean point spectra obtained from PIN at t (dataset 1) and t+12 
(dataset 2) with the difference between the curves illustrated   
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Wavenumber (cm-1) 
Absorbance 
 
Figure 3.19 Mean point spectra obtained from benign tissue at t+24, t+48, 
t+72 
 
 
In keeping with the findings shown in figures 3.18 and 3.19, there was no 
significant variation in the spectra obtained from all pathologies in section eight 
by FTIR over a three day period. This is reassuring as it implies that not only is 
FTIR analysis reproducible but also that the biochemical information contained in 
preserved sections does not degrade over time. 
 
3.3.3 The Effect of Co-scan Number on Prostate Tissue Analysis 
Each time point spectra are taken, the spectra recorded is a mean of the number of 
co-scans performed. Co-scans in infra-red spectroscopy refer to the co-adding of 
scans, this improves the signal to noise ratio. This is important because increasing 
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co-scan number achieves a higher signal to noise ratio but correlates with an 
increase in time taken for sample analysis. Therefore in these studies the co-scan 
number was varied but the aperture maintained at 30μm x 30μm and the spectral 
resolution set at 1cm-1. Targeted point spectra were taken from pathologies in 
section six which contained two pathologies; benign and malignant prostate tissue. 
Each measurement consisted of 20 spectra; measurements were repeated three 
times at each co-scan number setting. Both pathologies were evaluated at co-scan 
numbers 128, 75, 50, 25, 10, 5, 2 and 1. Figures 3.20 and 3.21 demonstrate the 
mean spectra obtained from each pathology at each co-scan setting. 
 
Absorbance 
Wavenumber (cm-1) 
 
Figure 3.20 Mean spectra obtained for benign tissue at labelled co-scan 
number 
 
 140
 Absorbance 
Wavenumber (cm-1) 
Figure 3.21 Mean spectra obtained for prostate cancer tissue at labelled co-
scan number 
Although all co-scan numbers yielded good spectra between wavenumbers 2000- 
1000 cm-1, the lowest co-scan number to achieve good quality spectra without noise 
between 2000 and 720 cm-1 was 25. There was uniformity in this finding in both 
pathologies. 
 
3.3.4 The Effect of Step Size in the Evaluation of Prostate Pathologies 
The studies prior to this section (section 3.3.3) describe the evaluation of the optimum 
FTIR software settings for analysis of prostate pathology. This section of the thesis 
addresses the potential limitation of point mapping in FTIR tissue analysis – step size. 
The concern regarding step size for evaluating prostate pathologies is chiefly the risk 
of missing valuable biochemical information between the steps during tissue analysis. 
This concept is illustrated in figures 3.22 and 3.23. 
 141
 
Sample 
30µm aperture 
Figure 3.22 Point mapping of fictitious sample with narrow steps 
 
 
Sample 
30µm aperture 
Figure 3.23 Point mapping of a fictitious sample with wide steps 
 
The aim of this step size study was to investigate the effect of increasing step size on 
the quality of spectral information obtained from individual pathologies. Radical 
prostatectomy specimen Nine, which contained three pathologies, was evaluated in 
this analysis using the optimum FTIR software settings determined in the previous 
studies: spectral resolution 1cm-1, number of co-scans 25, aperture 30μm x 30μm. 
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Step sizes ranging from 25μm to 500μm were examined. Benign prostatic hyperplasia 
was the pathology interrogated. Figure 3.24 shows the sample under analysis and 
figures 3.25, 3.26 and 3.27 illustrate the results.   
 
         
Figure 3.24 White light image of central part of prostate section nine (A) and 
close up image of BPH and selected area for point mapping (B) 
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Figure 3.25 Plot of mean spectra from all point maps of BPH at different spatial 
resolutions 
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  25μm 
Figure 3.26 PCA score maps of 
BPH measured in step size 
study 
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Figure 3.27 PCA loads for 
BPH measured in step size 
study 
The mean spectra obtained for individual pathologies during this analysis demonstrate 
that increasing step size does not have a significant detrimental effect on the mean 
spectra required to differentiate prostate pathologies. However close examination of 
the principal component loads and scores clearly illustrate that important biochemical 
information and detail is lost with increasing step size. This detail may yield 
important information regarding borders of pathology. Thus for the in depth analysis 
of pathologies or differentiation / region selection of subtleties, a smaller step size is 
mandatory. 
3.3.5 Commentary on point map technique validation studies 
Knowledge of the optimum FTIR parameters for tissue analysis is crucial for the 
development of the technique as a relevant clinical tool. This is particularly important 
because the goal of gold standard tissue analysis is to collect the necessary amount of 
information to diagnose and assess severity of pathology and thus guide patient 
management. FTIR clearly reproducibly interrogates more information than visual 
morphological analysis alone. The biochemical information attained by FTIR may at 
the minimum complement histological analysis but the potential to both automate and 
yield greater objective information regarding tissue under analysis is attractive. As a 
research tool it may facilitate a rapid way to understand more about prostate cancer 
biopotential as archival prostate tissue may be analysed with high sensitivity and 
specificity. Practically, for clinical applications a compromise regarding resolution 
and time efficiency may be sought. A thorough understanding of the biochemical 
information obtained by FTIR from prostate tissue would also be necessary before 
clinicians would consider adoption of the technique. The best way of obtaining 
detailed biochemical information may be by using FTIR in image mapping mode, to 
obtain fine detail about areas of interest.  This is shown in Figures 3.28 and 3.29, 
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which illustrate specific targeting of image mapping at pathologies within the radical 
prostatectomy specimens. 
 
Figure 3.28 Image map of area of PIN from prostatectomy section one; with 
mean spectra overlaid 
 
 
Figure 3.29 Image map of an area of prostate cancer from paraffinated 
prostatectomy section two; with mean spectra overlaid
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 3.4 Biochemical Analysis of Radical 
Prostatectomy Spectra 
This section describes the biochemical interpretations of spectra obtained from the 
radical prostatectomy studies, and attempts to apply a novel method of biochemical 
fitting of pure biochemical standards, using non-negative least squares analysis to 
describe the differences between pathologies.   
 
3.4.1 Parametric Non-Negative Least Squares Biochemical Fitting 
Discrimination between prostate pathologies has predominantly been on the basis of 
spectral characteristics and hypothesised underlying structural differences between 
pathologies to date. This section describes the experience of experimenting with a 
novel approach to achieving biochemical characterisation of prostate pathologies. The 
technique, in simple terms, involves combining the spectra from referenced pure 
biochemical standards to form a best fit curve, which best represents the spectra of the 
tissue pathology under analysis. The standards were measured locally and included 
constituents which were thought to best represent dominant components of prostate 
tissue. These constituents were deduced from the known biochemical reference peak 
assignments and accepted knowledge about cell constituents (i.e. proteins, amino 
acids, carbohydrates, lipids and nucleic acids). The component constituents were then 
fitted in various combinations against the mean spectra of each prostate pathology. 
The term residual is used in this study to define the difference between the 
constructed biochemical model spectra and the tissue pathology spectra. The 
concentrations of constituents (c) within the sample were estimated using parametric 
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non-negative least squares using the equation (1), where E is the matrix of the 
reference spectra and A is the measured composite spectra10: 
c =  (ETE)-1ETA  (1) 
The residuals visually demonstrate the quality of the biochemical model. In addition a 
process called orthogonality was performed to ensure that component spectra were 
not too similar. This was to avoid misjudging the component estimates. Orthogonality 
was calculated using the equation (2): 
a ● b = │a│ │b│ cosθ (2) 
A resulting dot product of 1 means no orthogonality and so perfect correlation, while 
a dot product of 0 represents no correlation and perfect orthogonality. In these 
experiments a threshold dot product of 0.95 was used to exclude components which 
were too similar to each other. Non-negative least squares fitting was applied to the 
radical prostatectomy spectral dataset described in section 3.2.1.2 from radical 
prostatectomy specimens one to five. In total, 1078 selected spectra were included 
from Benign, Malignant and PIN pathologies. The biochemical fitting was performed 
in Matlab® using programs written by Dr Martin Isabelle and Dr Nick Stone. Table 
3.12 illustrates the FTIR prediction of prostate pathology against histopathology; the 
sensitivity and specificity achieved by the three group algorithm was previously 
described in table 3.9. 
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  FTIR algorithm-predicted diagnosis (number of spectra) 
 Benign Prostate 
cancer 
PIN Total 
Benign 
 
400 64 26 490 
Prostate 
cancer 
60 396 10 466 
PIN 
 
18 7 97 122 
 
 
Histological 
Diagnosis 
(number of 
spectra) 
Total 
 
478 467 133 1078 
  
Table 3.12 FTIR prostate pathology prediction against histopathology 
 
Radical prostatectomy section one is used to illustrate the technique in practice below. 
Figure 3.24 illustrates the composite spectra of the pure biochemical composite 
spectra, and figure 3.25 the mean spectra of the pathologies. 
 
Figure 3.30 The composite spectra of dominant biochemical constituents 
 
800 1000 1200 1400 1600 1800 2000
0
0.2
0.4
0.6
0.8
1
1.2
1.4
 
 
HistoneAbsorbance 
Collagen I
Collagen IV
Palmitic Acid
Stearic Acid
RNA
Glucose
Lactate
Wavenumber (cm-1) 
 150
0.25
1400 1600
  
Figure 3.31 Plot of normalised mean spectra for each pathology type 
 
 
Biochemical fitting was then applied to the individual pathologies’ mean spectra and 
the results are illustrated in figures 3.32, 3.33 and 3.34. 
 
Figure 3.32 Sub-plot of residual versus mean spectra for each pathology after 
non-negative least squares fitting 
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Figure 3.33 Bar chart illustrating estimated relative concentration between 
pathologies as determined by non-negative least squares fitting 
 
 
 
Figure 3.34 3D-Barchart illustrating orthogonality between individual reference 
constituents  
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The reference spectral dataset was obtained by measuring proteins (histone, collagen I 
and collagen IV), lipids (palmitic acid and stearic acid), carbohydrates (glucose), 
carboxylic acid (lactate) and nucleic acid (RNA). The orthogonality illustrated in 
figure 3.34 was used to ensure that the component spectra were not too similar. 
Monitoring the residuals enabled the best possible biochemical fit to be achieved 
which is illustrated in figure 3.32. An 80 % fit was achieved using the component 
constituent spectra.. The differences in biochemical concentrations between the 
pathologies are summarised in table 3.13. The relationships are described, using 
arrows, as the latter against the former. 
 
 
Biochemical 
constituent 
concentration 
Benign vs. PIN PIN vs. Cancer Benign vs. Cancer 
Histone ▼ ▲ ▲ 
Collagen I ▲ ▼ ▼ 
Collagen IV ▲ ▼  
Palmitic acid  ▼ ▼ 
Stearic acid ▼   
Glucose ▼ ▲ ▲ 
Lactate ▲ ▼ ▼ 
RNA  ▲ ▲ 
 
Table 3.13 Relative differences in biochemical concentration between pathologies 
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Figure 3.35 Bar chart illustrating estimated benign relative biochemical 
concentrations in prostatectomy sections one to five 
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Figure 3.36 Bar chart illustrating estimated cancer relative biochemical 
concentrations in prostatectomy sections one to five 
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 Concentration 
Section 
 
Figure 3.37 Bar chart illustrating estimated PIN relative biochemical 
concentrations in prostatectomy sections one and four 
 
3.4.2 Commentary on non-negative least squares fitting study 
The non-negative least squares fitting analysis of prostatectomy section one shared 
some similar features with biochemical relationships in the other samples however the 
concentration ratio results were not reproduced in all of the sections. The hypothesis 
that increases in nucleic acids and DNA binding protein (histone) should be seen in 
malignant tissue due to an increase in nuclear to cytoplasmic ratio / mitotic activity 
and the hypothesis of higher glycolytic rates and anaerobic metabolism in tumour 
cells accounting for the changes in glucose and lactate in cancerous cells has not been 
proven in this analysis.  The black figures 3.35, 3.36 and 3.37 show the variance in 
relative biochemical concentrations between the prostatectomy sections for each 
individual pathology. Several factors may account for the lack of consistency of 
result: the cells of the tissue are likely to be in different stages of their cycle when 
analysed, and the tissue samples have different Gleason grades, which may mean that 
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in line with morphology the biochemistry of the tissues also changes. The major 
limitation of the non-negative least squares estimation method is that if one of the 
gross constituents in the model is unknown, the model may lead to biased estimations. 
In addition to this, the pure biochemical standards are not all from human sources and 
neither are they in the true cellular microenvironment when analysed, therefore it may 
be unsurprising that more conclusive findings have not been made. Future work may 
address this technique.  
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“ You see things and you say ‘why?’, I dream things that never were; and I say 
‘Why not?’ ”  
George Bernard Shaw 1856-1950 
4 Discussion 
 
4.1 Pilot Study Findings 
4.1.1 Summary of Pilot Study Findings 
Stain free FTIR imaging of snap frozen prostate tissue obtained at TURP was 
performed. Fourier Transform Infra Red spectra collected in imaging mode 
discriminated between benign and malignant prostate pathologies with high 
sensitivities and specificities. FTIR imaging enabled the fine detail of prostate 
histology to be interrogated and promising concordance was achieved between the 
histological diagnosis and FTIR algorithm especially in the four and six group 
algorithms which included ductal, glandular and stromal tissue. The differentiation 
between spectra from stroma associated with either benign or malignant tissue was 
particularly interesting because stroma is not normally utilised by the pathologist and 
this highlighted what FTIR could potentially add to conventional histology – total 
tissue analysis – this merits further investigation. Empirical analysis of the peak 
intensity ratios alone was not able to accurately differentiate between benign and 
malignant pathologies. Sophisticated multivariate analysis was used to achieve clear 
differentiation between pathologies and construct diagnostic algorithms. Cross 
validation of the two group algorithm using leave one sample out methodology 
achieved good results.  
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4.1.2 Pilot Study in the Context of the Literature  
The studies in this thesis were conceived, planned and performed between 2005 and 
2008. Prior to planning the studies, limited literature regarding the application of 
FTIR to prostate tissue analysis was available.  
Gazi et al had performed a pilot study investigating the potential of FTIR to 
differentiate between benign and malignant prostate epithelial cells in tissue obtained 
at TURP and cell lines1. The study contained small numbers of prostate samples (five) 
and used approximately four highly selected spectra per pathology upon which to base 
the conclusion that FTIR had the potential to rapidly discriminate between prostate 
pathologies including Gleason grade. Table 4.1 illustrates key differences between the 
Gazi study and the pilot study in this thesis. 
 
Study Gazi et al Aning 
Sample number (TURP 
chips) 
3 prostate cancer, 2 benign 4 prostate cancer, 23 
benign 
Primary tissue 
preparation 
Paraffin wax embedded Snap frozen 
FTIR imaging settings Bio-Rad FTS 6000 
spectrometer. 
Transmission mode. 
Number of co-scans 513, 
wavenumber range 750-
4000cm-1, spectral 
resolution 16 cm-1 
Perkin Elmer Spotlight 
300 spectrometer. 
Transmission mode. 
Number of co-scans 16, 
wavenumber range 720-
4000cm-1, spectral 
resolution 8 cm-1 
Number of spectra <100 used for analysis 12,309 used for analysis 
Peaks / peak ratios 
differentiating pathology 
1030cm-1/1080cm-1 1400cm-1/1450cm-1 
 
Table 4.1 The differences between the Gazi and Aning pilot studies 
 
Gazi’s pilot study was significant as its publication in the Journal of Pathology alerted 
clinicians and scientists to FTIR’s potential application as a diagnostic clinical tool 
because of its ability to discriminate between prostate pathologies. The pilot study in 
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this thesis was designed to establish primarily whether Gazi’s results were 
reproducible. Larger sample numbers and numbers of selected spectra were included; 
the sampling protocol was extended to include stromal, ductal and glandular areas 
within the tissue under interrogation. The results obtained in the pilot study in this 
thesis did not support the 1030cm-1/1080cm-1 peak ratio as the key discriminating 
factor between benign and malignant pathologies. This may have been because the 
sample areas in the study were more diverse, or alternatively the peak ratio difference 
may be accounted for by differences in cell cycle position at the time of analysis. The 
peak ratio 1400cm-1 / 1450cm-1 differed between pathologies, with the ratio closer to 
1.0 in malignant tissue as opposed to approximately 0.6 in benign tissue. This region 
corresponds to proteins and lipids (cholesterol) and may represent higher protein 
concentrations in cancerous cells with enlarged prominent nuclei. It has also been 
suggested that the amount of cholesterol in malignant tissues is lower2,3. 
 
Another explanation for the difference in spectra morphology between studies may be 
the fact that fresh snap frozen tissue rather than formalin fixed, archival de-
paraffinated tissue was evaluated. The effect of archiving or formalin cross-linkage 
with proteins in prostate tissue on FTIR spectra has not been previously reported, 
although its effect in prostate sub-cellular studies is acknowledged4. Despite the 
differences in spectral morphology, using multivariate analysis both studies 
demonstrated that FTIR has the potential to discriminate between benign and 
malignant prostate pathology. No attempt was made in the study to sub-classify 
spectra by Gleason grade, as the relative number of cancer samples within the cohort 
was small. This was a limitation of prospective prostate sample collection at TURP at 
which the yield of malignant tissue is expected to be low. Difficulties were 
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experienced in the sectioning of small fresh frozen prostate samples, which could be 
compared with corresponding H&E section under histological analysis. The only 
conclusion of the Gazi study which was not supported was with regard to speed of 
analysis; imaging of relatively small areas took a considerable amount of time even 
with a comparatively low co-scan number. 
 
Fernandez et al published work in April 2005 regarding FTIR imaging of 
microarrays, coupled with statistical pattern recognition techniques to differentiate 
benign from malignant prostate epithelium5. They proposed that by using this 
methodology, high throughput and fast classification, learning algorithms facilitated 
the measurement of all cell types including the least prevalent (for example nerves 
and lymphocytes). Each microarray contained 86 samples with up to eight samples 
each from 16 patients. In total the authors recorded over 9.5 million spectra from over 
870 samples and reported a subset of approximately 3 million spectra from 262 
samples. The paper quoted near perfect prostate pathology recognition accuracy. 
Whilst groundbreaking work, the results were almost too good; achieving over 95% 
classification accuracy in all but neural tissue. Fernandez et al acknowledged FTIR 
spectrometers may achieve high throughput and spatially resolved measurements but 
questioned how success in small studies would translate into practical clinical 
applications. if one was reliant on detecting significant biochemical changes in the 
form of spectral changes within small patient sets or by the examination of molecular 
moieties. Absence of suitable control samples has been cited as a limitation within 
previous FTIR studies. 
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The limitations of the pilot study were evident, as discussed in the commentary in the 
results section 3.1.6. However the promising pilot study findings merited further 
investigation of FTIR in tissue studies. The complex FTIR analysis proposed by 
Fernandez was not achievable within our laboratory and seemed to involve additional 
processing steps which FTIR as a technique intuitively was meant to avoid. 
Undoubtedly, the high throughput analysis of tissue microarrays, once validated, may 
represent the future in terms of evaluating large sample numbers in large phase trials 
however a thorough understanding of how FTIR may discriminate between 
pathologies is still necessary to judge its clinical niche and thus requires small scale 
tissue studies to continue. Prostate tissue is characteristically heterogeneous, therefore 
the FTIR prostate section studies were planned in the knowledge each section could 
act as its own intrinsic control.  
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4.2 FTIR Analysis of Prostatectomy Specimens 
4.2.1 Summary of the Results from FTIR Analysis of Radical Prostatectomy 
Sections 
FTIR analysis of nine radical prostatectomy sections in their entirety was performed. 
In knowledge of the constraints of image mapping in the pilot study, the concept of 
point mapping was explored. Formalin fixed prostate sections were interrogated in 
their paraffinated and deparaffinated forms. Interpretable spectra were obtained from 
both paraffinated tissue and deparaffinated tissue. The main pathologies present 
within the sections; benign tissue, prostate cancer and PIN were differentiated by both 
their spectra and multivariate analysis in paraffinated and deparaffinated 
corresponding sections. When the means of the total spectral data for all pathologies 
were examined, differentiation between pathologies was possible using the 1030cm-
1/1080cm-1 peak ratio proposed in Gazi’s pilot study1 however multivariate analysis 
was required to separate the pathologies more definitively. Superficially the three 
group model differentiated pathologies with reasonably good sensitivity and 
specificity. However when a diagnostic algorithm was constructed using the spectra 
from sections one to five and tested by leave one sample out validation, poor 
algorithm prediction was achieved. The model was then tested using a set of test 
spectra which had not been used to construct the model, and an even poorer 
performance of the diagnostic algorithm was achieved. Further investigation of the 
models poor performance was performed by re-analysing the individual section data. 
Sections which contained pathologist verified identical Gleason grade multifocal 
prostate tumours (without perineural invasion) were examined. It was evident from 
the spectra and multivariate analysis that although the pathologies may be of the same 
Gleason grade, their biochemical composition was different.  
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 Technical validation studies of the FTIR microspectrometer were then performed 
using the pathology within the radical prostatectomy sections. The analysis of the 
spectrometer was reproducible over a three day period without the need to purge the 
atmosphere in the spectrometer with an inert gas. Optimum co-scan number and step 
size were also assessed. Reproducibility of FTIR analysis was confirmed the optimum 
settings will be utilised in future studies. 
 
Non-negative least squares fitting was applied to the spectral dataset to attempt to 
classify changes in biochemical concentrations between pathologies, the findings 
were interesting but not robust more work is required to develop this technique.   
  
4.2.2 Radical Prostatectomy Study Findings in the Context of the Literature 
As far as the author is aware to date, the studies detailed in this thesis are the first to 
describe the FTIR analysis of radical prostatectomy specimens in their entirety, to 
follow through the concept of and the application of point mapping in prostate 
specimen analysis and to utilise FTIR to evaluate intra and inter patient pathologies 
and thus allowing for an adequate control for every FTIR measurement. 
 
Radical prostatectomy specimens proved excellent specimens for FTIR prostate tissue 
analysis. The advantages observed in this study were: 
• Each specimen acted as its own control 
• Each specimen contained multiple pathologies for analysis 
• The pathologists found it easier to clearly identify significant pathologies at 
which to target FTIR analysis 
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• The pathologists commented that radical prostatectomy specimens facilitated 
accurate Gleason grade allocation especially compared to the other tissues 
examined within this study. 
 
The use of radical prostatectomy specimens provided a robust test of FTIR’s true 
ability to discriminate between prostate pathologies. Multivariate analysis 
demonstrated good separation of benign tissue, malignant tissue and PIN, however the 
performance of the diagnostic algorithm was poor especially when a test spectra set 
was projected on the model. The poor performance is likely to be due to multiple 
factors: the small sample number (n=9), contaminants, the point map technique 
missing vital biochemical signatures between steps and potential misclassification of 
spectra in the model. However from the findings in this study – confirmed by follow 
up FTIR image mapping of specific areas, a hypothesis that the poor classification 
achieved by the model is due to the true heterogeneity in the biochemistry of tissue 
pathologies under analysis would not be unfounded. This is illustrated by the 
observation of biochemical differences between seemingly identical Gleason pattern 
tumours in this study. Although the patient numbers within this study are small, this 
finding supports the clinical concern that Gleason grade has significant limitations 
and tumours of the same Gleason grade may behave differently. Further work is 
required to study this finding in depth.  
 
It is clear from the studies in this thesis that the challenges of achieving a universal 
FTIR classification model are significant. Studies focusing on forming diagnostic 
algorithms based on the flawed Gleason classification, including highly selected 
spectra from small prostate samples, may not have widespread clinical application if 
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to tissue outside of the prostate transitional zone6,7,8. The transitional zone has been 
demonstrated to express a different FTIR biochemical signature to other prostate 
zones9, and the tumours which arise there may be clinically different to those that 
arise in the peripheral zone. In addition to this the majority of clinically significant 
prostate cancers are not diagnosed at TURP. Therefore in light of the findings of this 
thesis, broadening the horizons of specimen analysis to include radical prostatectomy 
specimens for all researchers in this field may in fact further enhance the credibility of 
FTIR analysis and its potential for automation.  
 
FTIR imaging of tissue enables fine detail analysis of prostate tissue. However it is 
time consuming and produces a huge amount of data which must be processed prior to 
analysis.  Practically, to achieve automation with current technology, a balance may 
have to be struck between the resolution of the technique i.e. sufficient to enable 
identification of pathology and analysis time. Point mapping allows larger sample 
areas to be examined in a reasonable period of time. The concern regarding point 
mapping is missing significant pathology, however it is envisaged by the author that 
image mapping of specific areas would complement abnormal areas identified using 
point mapping. The validation experiments enable the optimum characteristics to be 
used in future FTIR analysis. The limitation of point map techniques are 
acknowledged though10. 
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4.3 Comparison of Study Results with Other 
Spectroscopic Techniques 
Raman spectroscopy has achieved 89% accuracy, using leave one sample out 
validation, in the classification of BPH, Gleason <7, Gleason 7 and Gleason>7 when 
targeted at specific areas of pathology11. The diagnostic model in this study was 
constructed from 27 tissue samples and 450 spectra were recorded in total. The issue 
of control spectra has not been addressed in Raman studies of the prostate. The 
limitations of utilising Gleason grade, an imperfect standard, for the differentiation of 
prostate pathology has not been addressed. The potential for automation of the 
technique in the form of large section point map analysis has not to the authors 
knowledge been explored. Currently however it is not possible to measure good 
quality Raman spectra from paraffin embedded tissue12. This technology may 
compete in the future with FTIR as a pathological tool. OCT has yet to be applied to 
histological analysis of prostate tissue.  
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4.4 Conclusions 
Prostate cancer diagnostic strategies must evolve. The stimulus for this is not only 
novel technologies but also a drive from department of health policy makers to 
achieve early diagnosis and tailored patient management strategies in all cancers13. 
 
FTIR microspectroscopy has demonstrated in the studies in this thesis that it is a 
powerful bioanalytical technique which when combined with multivariate analysis 
has the ability to discriminate between prostate pathologies in snap frozen, 
paraffinated and deparaffinated tissue. The validation studies in this thesis have 
established that FTIR analysis is robust and versatile. Radical prostatectomy sections 
have been identified as a potential gold standard specimen for FTIR prostate tissue 
analysis.   
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4.5 Summary of Contribution to Knowledge  
 
• The studies in this thesis have demonstrated that FTIR is able to accurately 
identify benign, premalignant and malignant pathology in unstained snap 
frozen, parrifinated and deparrifinated prostate tissue.  
 
• The studies in this thesis have validated the results of previous pilot FTIR 
prostate tissue studies1 and in addition demonstrated that multivariate analysis 
refines the discrimination achieved between pathologies. 
 
• The studies in this thesis were the first to evaluate radical prostatectomy 
sections in their entirety and highlight the importance of having an appropriate 
control in order to truly validate FTIR studies. 
 
• The studies in this thesis were the first to analyse PIN and identify differences 
in the stroma surrounding benign and malignant glandular tissue. 
 
• The studies in this thesis were the first to introduce and investigate the concept 
of utilising non-negative least squares biochemical fitting to explain 
hypothesised FTIR structural differences between prostate pathologies.           
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4.6 Future Prospects 
The studies within this thesis and those performed by other groups have illustrated the 
potential for FTIR to be used as a pathology laboratory tool. Further work is required 
to increase the sample size used to construct the algorithms and the pathologies within 
them. This may require collaboration between different teams to achieve the large 
population required. Ultimately for FTIR to become established as a technique, the 
original work of Gleason must be replicated using FTIR instead of a pathologist and 
archival radical prostatectomy specimens instead of autopsy prostates.  
The prostate core biopsy specimens detailed in the methodology section were 
collected and analysed at the end of the research period in late 2007. Due to time 
constraints and the necessity to share the Biophotonic Research Group facilities these 
specimens have been FTIR image mapped but not fully analysed. The intention was 
primarily to use these biopsy specimens as a test spectra group to blind test the TURP 
algorithm. The prostate cores were also to be used to investigate whether: the spectra 
obtained from non-malignant specimens in patients whose other prostate biopsies 
were also benign, were different to, the spectra obtained in non malignant specimens 
from patients whose other prostate biopsies were positive for prostate cancer.  The 
next investigator will pursue this work in addition to attempting to create a FTIR 
spectral and hence biochemical representation of a whole prostate and including all 
the pathology contained within the specimen. 
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